Category: For physicians

  • Dr. Gurpreet Singh Padda beside the title card reading She's Not Allergic to Her Food. She's Fermenting It., The Angry Gut, Chapter 31

    Low Dose Naltrexone Mechanism of Action: Four Links, Each With a Tier

    She's Not Allergic to Her Food. She's Fermenting It. | The Angry Gut, Chapter 31

    Low Dose Naltrexone Mechanism of Action: Four Links, Each With a Tier

    Low dose naltrexone works indirectly, through a chain of four links: a rebound rise in beta-endorphin, intermittent rather than continuous receptor blockade, effects on lymphocytes and regulatory T cells, and antagonism of Toll-like receptor 4. It is not a mast cell stabilizer.

    The low-dose naltrexone mechanism most often repeated is the one the pharmacology does not support. The one that survives is indirect, upstream, and graded link by link.

    Ask ten clinicians for the low dose naltrexone mechanism of action and several will call it a mast cell stabilizer. It is not, and the error matters because it sets the wrong expectations and the wrong endpoints. The mechanism that holds up is a chain of four links, each resting on a different grade of evidence.

    The Angry Gut by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes applies that chain, in the chapter video She’s Not Allergic to Her Food. She’s Fermenting It., to a patient with gut-predominant mast cell symptoms. Measura [Cardiometabolic and Autonomic Health Analysis] reports objective measurements to the clinician who orders them and neither diagnoses, treats nor prescribes. The pharmacology below is for interpretation and co-management, not a recommendation to start or change any drug.

    Link one: the rebound, measured in human CSF

    The therapeutic event is the rebound, not the blockade. At a standard rather than low dose, naltrexone raised cerebrospinal fluid beta-endorphin from 1.15 to 2.03 fmol/mL while POMC did not move, so the beta-endorphin-to-POMC ratio rose 80%, holding after two and seven days. Two details inside that study bear on patient selection. Among fourteen healthy volunteers, overweight and obese subjects showed a 138% increase versus 52.1% for the lean group, so the metabolically loaded patient may mount the larger response. And plasma cortisol rose from 12.4 to 15.6 µg/dL, a 28% increase. A drug that lifts endorphin and cortisol together is not a clean intervention.

    Link two: duration of blockade, not dose

    Three decades of laboratory work converge on one principle: intermittent blockade at low doses depressed cell replication, while continuous blockade at high doses enhanced it. The full 100 mg dose occupies 92% of kappa receptors on PET, and in that alcohol-use cohort higher occupancy went with more craving, not less. Occupancy in the 1.5 to 4.5 mg range has never been imaged in humans. The main metabolite, 6beta-naltrexol, is itself an antagonist with a terminal half-life of 11.1 hours, so whether a bedtime dose is still intermittent by morning is unmeasured. That is the gap in the dose rationale, stated plainly.

    Link three: lymphocytes and Tregs

    Of the four, this link carries the weakest evidence. Whether immune cells express opioid receptors is contested, with some groups confirming mRNA and protein and others finding no message. In female mice, regulatory T cells produced enkephalin that engaged sensory-neuron delta opioid receptors and dampened nociception, a function separable from immunosuppression and dependent on sex hormones. Tregs and the opioid system are coupled; the direction of traffic in humans is not established. The widely quoted sentence that endorphins bind Tregs to reduce cytokines traces to a single case report in which one patient received naltrexone, immunoglobulin and antibiotics together.

    Human data are limited to downstream output. Following an eight-week course in eight women with fibromyalgia, eighteen plasma mediators fell, including IL-1β, IL-6, IL-17A and TNF-α, with pain down 15%. Anti-inflammatory mediators such as IL-10 fell too, and no multiplicity correction was described. It is a signal, not a clean anti-inflammatory effect.

    Link four: TLR4, stated narrowly

    Naltrexone and naloxone antagonize Toll-like receptor 4, the lipopolysaccharide receptor. In the defining experiment all four isomers, including the clinical (−)-naltrexone, attenuated LPS-induced signaling in a cell line by non-competitive inhibition, but the microglial and animal work used the (+)-isomers and (−)-naloxone. Naltrexone shows no stereoselectivity at TLR4, which is why the clinical isomer works at all, and it is weak, roughly 25 times less potent than an optimized bivalent ligand. The (+)-isomers inhibited nitric oxide and TNF-α but not IL-1β, and not NF-κB, p38 or JNK signaling; the blocked arm was TRIF-IRF3-interferon. No human study has shown low-dose naltrexone antagonizing TLR4. The tier is cellular and animal.

    MRGPRX2: why it is not a stabilizer

    Opioids degranulate mast cells through MRGPRX2, outside the classical opioid system. Naltrexone is inactive there, neither agonist nor antagonist, and naloxone at 10 µM did not alter opioid-induced degranulation in a human mast cell line. In the animal spinal mass model, scores were 2.3 with morphine and 2.5 with morphine plus naltrexone, while cromolyn blocked the damage. None of that contradicts the chain above. The route is indirect and upstream: endorphin rebound acting on the lymphocyte compartment, and TLR4 antagonism thinning the cytokine traffic that keeps mucosal mast cells primed. Quieting follows without the drug touching the mast cell membrane.

    Low dose naltrexone mechanism of action in the clinical record

    • Crohn’s disease, randomized: two trials, 46 participants. Remission 30% against 18%, not significant; 70-point response 83% against 38%, significant; endoscopic response 72% against 25%. GRADE low for imprecision.
    • Fibromyalgia, randomized: four trials, 222 patients, pooled pain reduction of −0.86 points; the largest trial, 6 mg for twelve weeks, missed its primary endpoint.
    • IBS: open-label only, 0.5 mg daily, global improvement in 76% of 42 patients.
    • Practice-level data: a survey of 553 patients rated benefit 5.6 of 10, equal to benzodiazepines and below antihistamines at 6.3; a dysautonomia chart review found no significant change on a validated autonomic instrument, with pain improvement documented in 24.14%.

    Where objective measurement fits

    Tryptase, histamine and mast cell testing are specialized studies done elsewhere; Measura does not run them beyond general laboratory panels. Under the restrictive consensus, normal serum tryptase is 0 to 11.4 ng/mL and an episode is defined by tryptase exceeding 1.2 times baseline plus 2 ng/mL, and every one of the three criteria is required.

    What Measura can document is the comorbid terrain. Orthostatic intolerance was the prescribing reason in 27.78% of that dysautonomia review, and the null there was on a questionnaire. Two biological drivers keep this population primed, endotoxin crossing a damaged barrier and metaflammation in the first brain, and one structural one: every comorbidity is an exclusion criterion somewhere, so the trial population never matches the clinic. Objective baselines help close that gap:

    Selection and ordering are covered under clinical selection criteria and specialty applications. The patient version of this topic is here, the autonomic overlap is developed in orthostatic intolerance screening, and the study-level limits are in the Chapter 31 Deep Dive.

    Frequently asked questions

    Does naltrexone act directly on mast cells?

    Not through the pathway that matters for opioid-driven degranulation. Naltrexone is inactive at MRGPRX2, and naloxone did not alter opioid-induced degranulation in a human mast cell line. Any effect on mast cell activity is indirect, through endorphin rebound on lymphocytes and TLR4 antagonism reducing upstream cytokine priming. Cromolyn remains the membrane stabilizer. Read the clinical rationale for the protocol.

    Why would a low dose work differently from a full dose?

    The laboratory literature points to duration of receptor blockade rather than dose: intermittent blockade depressed cell replication and continuous blockade enhanced it. The full 100 mg dose occupies 92% of kappa receptors, but occupancy at 1.5 to 4.5 mg has never been measured in humans, and the active metabolite’s 11.1-hour half-life complicates the intermittency assumption. See answers to common physician questions.

    Is the TLR4 effect established in patients?

    No. TLR4 antagonism by naltrexone rests on cell-line and animal work, with non-competitive inhibition and no stereoselectivity. The narrower finding is that the isomers tested inhibited TNF-α and nitric oxide but not IL-1β. No human study has shown low-dose naltrexone antagonizing TLR4, so it should be documented as mechanism tier. See how Measura results are reported.

    Which patients with mast cell symptoms merit autonomic testing?

    Patients reporting lightheadedness or tachycardia on standing, those with hypermobility or a dysautonomia label, and anyone in whom a treating physician wants an objective baseline rather than a questionnaire. Autonomic findings document comorbid physiology; they neither confirm nor exclude mast cell activation, which requires tryptase-based criteria done elsewhere. Review standing orders for screening.

    How should mechanism tiers be documented in the chart?

    Record the diagnostic criteria set used, paired tryptase values if obtained elsewhere, objective autonomic and body composition baselines, and a planned re-measure date. Stating which claims are established, mechanistic or practice-based keeps later interpretation honest and supports structured quality documentation without implying a diagnosis the testing does not make. See how results reach the record.

    See how autonomic baselines fit a complex-patient workflow

    Learn how Measura autonomic, heart rate variability and body composition testing can document the comorbid terrain in patients under evaluation for mast cell activation.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Gordon, R. J., Panigrahi, S. K., Meece, K., Atalayer, D., Smiley, R., & Wardlaw, S. L. (2017). Effects of opioid antagonism on cerebrospinal fluid melanocortin peptides and cortisol levels in humans. Journal of the Endocrine Society, 1(10), 1235-1246. https://doi.org/10.1210/js.2017-00289
    • McLaughlin, P. J., & Zagon, I. S. (2015). Duration of opioid receptor blockade determines biotherapeutic response. Biochemical Pharmacology, 97(3), 236-246. https://doi.org/10.1016/j.bcp.2015.06.016
    • de Laat, B., Nabulsi, N., Huang, Y., O’Malley, S. S., Froehlich, J. C., Morris, E. D., & Krishnan-Sarin, S. (2020). Occupancy of the kappa opioid receptor by naltrexone predicts reduction in drinking and craving. Molecular Psychiatry, 26(9), 5053-5060. https://doi.org/10.1038/s41380-020-0811-8
    • Midavaine, E., Moraes, B. C., Benitez, J., Rodriguez, S. R., Braz, J. M., Kochhar, N. P., Eckalbar, W. L., Tian, L., Domingos, A. I., Pintar, J. E., Basbaum, A. I., & Kashem, S. W. (2025). Meningeal regulatory T cells inhibit nociception in female mice. Science, 388(6742), 96-104. https://doi.org/10.1126/science.adq6531
    • Parkitny, L., & Younger, J. (2017). Reduced pro-inflammatory cytokines after eight weeks of low-dose naltrexone for fibromyalgia. Biomedicines, 5(2), 16. https://doi.org/10.3390/biomedicines5020016
    • Hutchinson, M. R., Zhang, Y., Brown, K., Coats, B. D., Shridhar, M., Sholar, P. W., Patel, S. J., Crysdale, N. Y., Harrison, J. A., Maier, S. F., Rice, K. C., & Watkins, L. R. (2008). Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: Involvement of toll-like receptor 4 (TLR4). The European Journal of Neuroscience, 28(1), 20-29. https://doi.org/10.1111/j.1460-9568.2008.06321.x
    • Wang, X., Zhang, Y., Peng, Y., Hutchinson, M. R., Rice, K. C., Yin, H., & Watkins, L. R. (2016). Pharmacological characterization of the opioid inactive isomers (+)-naltrexone and (+)-naloxone as antagonists of toll-like receptor 4. British Journal of Pharmacology, 173(5), 856-869. https://doi.org/10.1111/bph.13394
    • Lansu, K., Karpiak, J., Liu, J., Huang, X.-P., McCorvy, J. D., Kroeze, W. K., Che, T., Nagase, H., Carroll, F. I., Jin, J., Shoichet, B. K., & Roth, B. L. (2017). In silico design of novel probes for the atypical opioid receptor MRGPRX2. Nature Chemical Biology, 13(5), 529-536. https://doi.org/10.1038/nchembio.2334
    • Parker, C. E., Nguyen, T. M., Segal, D., MacDonald, J. K., & Chande, N. (2018). Low dose naltrexone for induction of remission in Crohn’s disease. Cochrane Database of Systematic Reviews, 4(4), CD010410. https://doi.org/10.1002/14651858.CD010410.pub3
    • Zapata, N., Georgiadi, E., Cantrell, C., Rilinger, R. G., Levine, M. A., & Wilson, R. (2025). Low-dose naltrexone for managing pain and autonomic symptoms in patients with dysautonomia. Cureus, 17(6), e86538. https://doi.org/10.7759/cureus.86538

    Related reading

  • Dr. Gurpreet Singh Padda beside the title card reading There Is No Discharge Date, The Angry Gut, Chapter 30

    Patient Activation Measure: Why Maintenance Needs Objective Re-Testing

    There Is No Discharge Date | The Angry Gut, Chapter 30

    Patient Activation Measure: Why Maintenance Needs Objective Re-Testing

    Patient activation measure scores related to 12 of 13 outcomes in 25,047 primary care patients, but lifestyle results decay as treatment intensity falls, so maintenance needs objective metabolic re-testing on a fixed schedule. Set a baseline at the end of the intensive phase and write a defined repeat date into the order.

    Every long lifestyle trial draws the same curve: intensity decays and the result decays with it. A practice cannot hold intensity constant, but it can standardize what gets re-measured and when.

    Scores on a patient activation measure predict outcomes that the ritual of consultation does not, and the durability literature explains why that matters for the maintenance phase. Lifestyle treatment works while it is delivered at dose and erodes as the dose falls. The one variable a practice fully controls in year two is whether anyone is measuring the erosion.

    The video There Is No Discharge Date, from The Angry Gut by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes, frames maintenance as an agricultural job rather than a curative one. Measura [Cardiometabolic and Autonomic Health Analysis] measures and reports to whoever ordered the testing, and diagnosis and treatment stay with that clinician. What follows is the screening and re-testing logic that framing implies.

    The durability record, read for its design

    The original prevention trial enrolled 3,234 nondiabetic adults with impaired glucose tolerance, mean age 51, mean BMI 34.0, 68 percent women and 45 percent from minority groups, followed for an average of 2.8 years. A 7% weight-loss target plus 150 minutes of weekly activity cut incidence by 58%, against 31% for metformin. The winning arm was an individually delivered curriculum with case managers, not advice.

    The fifteen-year follow-up retained 2,776 participants, 88% of the surviving cohort. Cumulative incidence converged to 55%, 56% and 62%, with a hazard ratio of 0.73 for lifestyle, and the aggregate microvascular outcome did not separate by arm. Two design facts govern interpretation. After the randomized phase every participant was offered lifestyle training, so the comparison is of initial assignment rather than maintained regimens. And protection followed the achieved outcome: those who avoided diabetes by any route had 28% fewer microvascular complications. In women, lifestyle carried a microvascular prevalence of 8.7% against 11.0% on placebo and 11.2% on metformin, a subgroup finding measured once at study end.

    Look AHEAD randomized 5,145 overweight or obese adults with type 2 diabetes, median follow-up 9.6 years and maximum 13.5, and stopped for futility on the cardiovascular endpoint. The intensive arm still improved glycated hemoglobin, fitness and every risk factor except LDL cholesterol, while the comparison arm also lost weight and pharmacotherapy improved in both. It tested calorie restriction and activity, not diet quality. A null on that question is not a null on terrain repair.

    Outside trials, the national prevention program enrolled 14,747 adults. Participants reported a weekly average of 152 minutes of activity, median 128, with 41.8% meeting the 150-minute goal, and weight loss rose with sessions attended. The authors named retention as the fix.

    Patient activation measure scores versus consultation

    In 25,047 insured primary care patients scored once and matched to their records, activation related to 12 of 13 outcomes across prevention, unhealthy behaviors, clinical indicators and utilization. The design is cross-sectional in one health system, so activation may partly report good health rather than produce it.

    Shared decision-making, studied in 396 patients with COPD or asthma, showed no association with medication adherence, an odds ratio of 1.01, with complete adherence at 41.2%. The mean score on the decision-making instrument was 26.7 on a scale running to 45, which leaves little room to detect an effect. Consulted and capable are different states, and neither study tested teaching a patient the mechanism of their own disease. Objective, repeated numbers are one concrete way to build that capability: a patient who can read a trend can adjust before the next visit.

    Why the terrain argues for individual re-measurement

    Two upstream biological drivers set the maintenance problem. The first is the microbial community of the first brain, the gut. In the seventeen-week feeding trial, 39 adults were assigned and 18 per arm analyzed; high-fiber eaters split into three distinct immune trajectories sorted by baseline microbiota diversity. In 800 people across 46,898 meals, glycemic responses to identical food varied widely, and a model integrating blood parameters, anthropometrics, activity and microbiota was checked in an independent 100-person cohort. In mice held on low fiber for four generations, 141 of 208 taxa did not return with fiber alone. The second driver is metaflammation and insulin resistance, which drift silently while weight looks stable. The third is structural: programs designed around attendance lose the dose, and the patient absorbs the cost in disease.

    Heterogeneous response plus decaying intensity means a population protocol cannot tell you which patient is slipping. A measured baseline and scheduled repeats can.

    What to re-measure, and what a finding changes

    • Laboratory panels: glycemic markers, fasting insulin and lipids. A rising insulin requirement at stable weight is an indication to intensify behavioral support before glucose crosses a threshold.
    • Bioimpedance body composition: separates fat regain from lean loss, which weight alone conflates.
    • Indirect calorimetry: measured resting energy expenditure after substantial loss, replacing a predictive equation when setting intake targets.
    • Sudomotor testing: sweat-gland function of small nerve fibers in the hands and feet, relevant because neuropathy sat inside the aggregate microvascular outcome.
    • Heart rate variability: a documented autonomic baseline for patients whose vagal tone is part of the plan.

    Liver histology is a different study done elsewhere, though it makes the dose point cleanly: among patients with biopsy-confirmed NASH who lost at least 10% of body weight, 90% resolved and 45% had fibrosis regress. In older patients, the year-long Mediterranean trial in 612 adults aged 65 to 79 linked adherence-favored organisms to less frailty and better cognition, which makes a cognitive assessment baseline and fall-prevention pairing reasonable in the same encounter.

    Workflow and documentation

    A standing order keyed to completion of an intensive lifestyle phase removes the dependence on someone remembering to re-test; the logic is laid out in making screening reproducible. Between visits, the chronic care and monitoring structure carries the trend. Record the selection criterion, the baseline values and the planned re-measure date together so change is interpretable and supports quality reporting. The prevention-program piece for physicians is diabetes prevention program screening, the patient version of this topic is here, and the study-level limits are in the Chapter 30 Deep Dive. The next physician article covers the low-dose naltrexone mechanism of action.

    Frequently asked questions

    Does patient activation cause better outcomes or just reflect them?

    The largest study is cross-sectional: 25,047 patients scored once in a single insured system, with activation related to 12 of 13 outcomes. That design cannot separate cause from marker, and the least engaged patients are least likely to be in the denominator. It still supports building capability deliberately rather than assuming consultation supplies it. Read what changes for the patient.

    Does the Look AHEAD null mean lifestyle treatment fails in type 2 diabetes?

    It means calorie restriction and activity did not reduce cardiovascular events over a median 9.6 years while the comparison arm also improved. Glycated hemoglobin, fitness and most risk factors still favored the intensive arm, and diet quality was never the intervention. The trial did not test the question most maintenance plans ask. Read the clinical rationale for the protocol.

    How often should metabolic measures be repeated in the maintenance phase?

    The trials show intensity and results decaying together, so the interval should shorten when support tapers, not lengthen. A practical approach sets a baseline at the end of the intensive phase and a defined repeat date in the order itself, adjusted by the treating physician for risk and prior trend. See how to interpret the report.

    Which patients should be prioritized for re-testing?

    Patients finishing an intensive lifestyle program, those with impaired glucose tolerance at entry, patients with a large weight loss where predictive equations misfit, and older adults in whom frailty and cognition are live concerns. Poor attendance is a selection criterion, not an exclusion, because that is where the dose went missing. Review the selection criteria.

    How should maintenance-phase results be documented for quality programs?

    Record baseline and repeat values at defined intervals with the selection criterion that triggered testing, so the chart shows a trend rather than isolated snapshots. Structured results fit annual wellness visit documentation and quality measures without implying a diagnosis the testing does not make. See MIPS and quality reporting guidance.

    See how re-measurement fits a maintenance program

    Learn how Measura laboratory, body composition and autonomic testing can run on standing orders at the end of an intensive lifestyle phase and at scheduled repeats.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Greene, J., & Hibbard, J. H. (2012). Why does patient activation matter? An examination of the relationships between patient activation and health-related outcomes. J Gen Intern Med, 27(5), 520-6. https://doi.org/10.1007/s11606-011-1931-2
    • Achterbosch, M., Vart, P., van Dijk, L., & van Boven, J. F. M. (2023). Shared decision making and medication adherence in patients with COPD and/or asthma: the ANANAS study. Front Pharmacol, 14, 1283135. https://doi.org/10.3389/fphar.2023.1283135
    • Knowler, W. C., Barrett-Connor, E., Fowler, S. E., Hamman, R. F., Lachin, J. M., Walker, E. A., Nathan, D. M., & Diabetes Prevention Program Research Group. (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med, 346(6), 393-403. https://doi.org/10.1056/NEJMoa012512
    • Diabetes Prevention Program Research Group. (2015). Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol, 3(11), 866-75. https://doi.org/10.1016/S2213-8587(15)00291-0
    • Wing, R. R., Bolin, P., Brancati, F. L., Bray, G. A., Clark, J. M., Coday, M., Crow, R. S., Curtis, J. M., Egan, C. M., Espeland, M. A., Evans, M., Foreyt, J. P., Ghazarian, S., Gregg, E. W., Harrison, B., Hazuda, H. P., Hill, J. O., Horton, E. S., Hubbard, V. S., … Yanovski, S. Z. (2013). Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med, 369(2), 145-54. https://doi.org/10.1056/NEJMoa1212914
    • Ely, E. K., Gruss, S. M., Luman, E. T., Gregg, E. W., Ali, M. K., Nhim, K., Rolka, D. B., & Albright, A. L. (2017). A National Effort to Prevent Type 2 Diabetes: Participant-Level Evaluation of CDC’s National Diabetes Prevention Program. Diabetes Care, 40(10), 1331-1341. https://doi.org/10.2337/dc16-2099
    • Wastyk, H. C., Fragiadakis, G. K., Perelman, D., Dahan, D., Merrill, B. D., Yu, F. B., Topf, M., Gonzalez, C. G., Van Treuren, W., Han, S., Robinson, J. L., Elias, J. E., Sonnenburg, E. D., Gardner, C. D., & Sonnenburg, J. L. (2021). Gut-microbiota-targeted diets modulate human immune status. Cell, 184(16), 4137-4153.e14. https://doi.org/10.1016/j.cell.2021.06.019
    • Zeevi, D., Korem, T., Zmora, N., Israeli, D., Rothschild, D., Weinberger, A., Ben-Yacov, O., Lador, D., Avnit-Sagi, T., Lotan-Pompan, M., Suez, J., Mahdi, J. A., Matot, E., Malka, G., Kosower, N., Rein, M., Zilberman-Schapira, G., Dohnalova, L., Pevsner-Fischer, M., … Segal, E. (2015). Personalized Nutrition by Prediction of Glycemic Responses. Cell, 163(5), 1079-1094. https://doi.org/10.1016/j.cell.2015.11.001
    • Sonnenburg, E. D., Smits, S. A., Tikhonov, M., Higginbottom, S. K., Wingreen, N. S., & Sonnenburg, J. L. (2016). Diet-induced extinctions in the gut microbiota compound over generations. Nature, 529(7585), 212-5. https://doi.org/10.1038/nature16504
    • Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015). Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology, 149(2), 367-78.e5. https://doi.org/10.1053/j.gastro.2015.04.005

    Related reading

  • Dr. Gurpreet Singh Padda beside the title card reading A Plateau Is Not a Personality, The Angry Gut, Chapter 29

    Intestinal Permeability Test: Endpoints for a Stalled Gut Protocol

    A Plateau Is Not a Personality | The Angry Gut, Chapter 29

    Intestinal Permeability Test: Endpoints for a Stalled Gut Protocol

    The intestinal permeability test to use is the dual-sugar lactulose-to-mannitol ratio, ordered through gastroenterology or a reference laboratory, not serum zonulin. Measure it before a repair protocol starts and set the repeat date in advance; the controlled glutamine trial remeasured at the end of its eight-week course.

    A patient who plateaus on a gut repair plan needs an endpoint, not another supplement. The dual-sugar test supplies one, and the metabolic terrain around the barrier deserves the same discipline.

    An intestinal permeability test earns its place when a patient has addressed the obvious drivers and still has not recovered. Chapter 29 of The Angry Gut, by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes, is presented in the video above, A Plateau Is Not a Personality, through a patient about sixty percent improved for five months whose lactulose-to-mannitol ratio stayed elevated after medications, sleep, diet and bile flow had been corrected. The argument is methodological: a measured baseline, doses matched to the trials that tested them, and a remeasurement date fixed before treatment begins.

    Serum zonulin is not a permeability measure

    Three independent validation studies set the widely used commercial zonulin kit against measured permeability: R = 0.11 in 38 subjects, R = 0.17 in 71 and R = 0.033 in 24, none significant, 133 people in all. The kits were built against the first published zonulin sequence, later shown to be unrelated to the protein, and in serum from 376 members of the Sorbs cohort none of the proteins the antibody captured corresponded to pre-haptoglobin-2. Alessio Fasano, who first described zonulin, co-authored that correction. The reviewers’ recommendation was dual-sugar assays and tissue-level measures, and because pre-haptoglobin-2 is not naturally expressed in mice, rodent serum zonulin findings inherit the problem.

    How the dual-sugar intestinal permeability test works, and why it is repeated

    Mannitol, the smaller probe, crosses transcellularly and reflects absorptive surface; lactulose crosses paracellularly when junctions loosen. Neither is metabolized, both are excreted in urine over roughly six hours, and the ratio cancels gastric emptying, ingested volume and renal clearance. It is cumbersome and produces no colored report, but it measures the barrier. It is not a Measura test; it is ordered through gastroenterology or a reference laboratory.

    Repetition is the point. In the case above the ratio returned to range at twelve weeks; those are practice-reported figures from our own population, not trial outcomes, and individual results vary. Symptom reports are a weak substitute. In a three-arm, open-label polaprezinc eradication trial run across 11 Chinese cities, all arms reported significant symptom improvement at 7, 14 and 28 days, including the arm that received antibiotics alone.

    Enrollment determines effect size

    Glutamine shows why selection matters. In adults with post-infectious diarrhea-predominant IBS and documented hyperpermeability, 5 g three times daily for eight weeks produced a fifty-point symptom response in 79.6% against 5.8% on placebo, and the lactulose-to-mannitol ratio fell from 0.11 to 0.05, returning to range only in the treated group. A meta-analysis of 39 human glutamine studies, largely in surgical and critically ill patients, found a pooled ratio change of 0.01. The single trial’s effect is much larger because it admitted only patients with a measured leak, excluding everyone with nothing to fix. It comes from one group without replication, and its authors asked for validating trials.

    Dr. Padda spent years telling patients that a lining which renews in days needs only rest and time. That holds for acute injury. For a barrier measured open over years, the screening implication is direct: measuring before treating selects the patients most likely to respond and supplies the endpoint that makes a response interpretable.

    Dose provenance and endpoint mismatch

    Several agents common in gut protocols carry doses from trials that never measured the barrier. Zinc carnosine prevented an indomethacin-induced permeability rise in 10 healthy volunteers at 37.5 mg twice daily, while the 75 mg twice-daily retail dose derives from Helicobacter pylori eradication trials; doubling to 150 mg twice daily added no eradication benefit as adverse events rose from 2.8% to 5.1%. Oral GABA doses come from stress and sleep research, and none of the 14 included studies measured a gastrointestinal endpoint. Larazotide acetate, the only junction-targeted drug taken to phase 3, did not separate from placebo on the dual-sugar ratio in pooled analysis, and phase 3 was terminated without a published efficacy figure. Symptom relief and measured permeability can dissociate, and agent selection remains with the treating clinician.

    Nutrient status and the metabolic terrain

    Supply deficits are checkable. The global estimate that 17.3% of people are at risk of inadequate zinc intake is a food-supply model; risk rose with the phytate-to-zinc ratio and fell with animal-source zinc, and its authors called for direct biochemical assessment instead of inference. A randomized trial gave 27 Crohn’s patients in remission vitamin D at 2,000 IU a day; permeability held steady on treatment while the placebo arm worsened, and those reaching 75 nmol/L had lower CRP (p = 0.019), a post-hoc responder analysis that favors dosing to a measured level. Glycine synthesis plus diet falls about 10 g a day short of demand in a 70 kg adult, a flux calculation rather than a demonstrated deficiency. The economic driver is the food supply itself: low-priced grain and legume staples carry their own zinc blocker.

    The patient who plateaus is also the patient trials exclude, with metabolic disease, a long medication list and disrupted sleep. That is where Measura [Cardiometabolic and Autonomic Health Analysis] applies. It does not measure intestinal permeability. It measures the terrain: laboratory panels for insulin resistance and inflammation, the metaflammation that travels with barrier failure; bioimpedance body composition for lean mass in patients whose diets have narrowed; and indirect calorimetry for measured resting energy expenditure, so nutrition plans for a rebuilding barrier rest on measured demand rather than an estimate. In the book’s language the gut is the first brain and the skull holds the second brain, and these measures describe the metabolic environment both share.

    Selection criteria and documentation

    Written selection criteria can flag patients with persistent gastrointestinal symptoms plus metabolic risk factors for cardiometabolic measurement, and standing orders keep that consistent. A baseline and a predefined repeat interval, documented through getting results into the record, turn a plateau into a trackable course. The patient version is how long it takes to heal leaky gut; the bile acid workup precedes it in postcholecystectomy diarrhea; and the full study data with limits are in the Chapter 29 companion.

    Frequently asked questions

    When is an intestinal permeability test worth ordering?

    When a gastrointestinal plateau persists after identifiable drivers such as medications, sleep, diet and bile flow have been addressed, or before a repair protocol begins so there is an endpoint to return to. A dual-sugar ratio with a scheduled repeat distinguishes an open barrier from a slow symptomatic recovery. The case for measuring before managing is set out in clinical rationale.

    Does Measura perform dual-sugar permeability testing?

    No. The lactulose-to-mannitol test is ordered through gastroenterology or a reference laboratory. Measura measures the surrounding terrain, including laboratory panels for insulin resistance and inflammation, body composition and resting energy expenditure, and returns findings to the ordering physician. How these measures fit different practice types is described in specialty applications.

    How soon should permeability be remeasured?

    Set the interval before treatment starts and match it to the protocol being tested. The controlled glutamine trial remeasured at the end of its eight-week course, which is a defensible default for that intervention. A symptom diary alone is unreliable, since open-label trials show improvement in every arm. Tracking values across that interval is covered in chronic care and between-visit monitoring.

    Should zinc and vitamin D status be checked before a gut repair protocol?

    The sources favor measurement over assumption. The global zinc estimate is a food-supply model whose authors asked for direct biochemical assessment, and the vitamin D trial in Crohn’s disease pointed to a blood level of 75 nmol/L rather than a fixed dose. Laboratory results read in context are discussed in interpreting the report.

    Why add indirect calorimetry or body composition for a gut patient?

    Patients on long gut protocols often narrow their diets, and a barrier under repair depends on substrate supply. Measured resting energy expenditure shows whether intake meets demand, and body composition shows whether lean mass is holding. Both give the plateau a metabolic baseline alongside the permeability endpoint. The difference between measured and predicted energy use is covered in measured versus estimated metabolic rate.

    Give every protocol an endpoint

    Learn how the Measura protocol adds laboratory, body composition and resting metabolic rate measurement to the follow-up your practice already schedules.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Massier, L., Chakaroun, R., Kovacs, P., & Heiker, J. T. (2021). Blurring the picture in leaky gut research: How shortcomings of zonulin as a biomarker mislead the field of intestinal permeability. Gut, 70(9), 1801-1802. https://doi.org/10.1136/gutjnl-2020-323026
    • Scheffler, L., Crane, A., Heyne, H., Tönjes, A., Schleinitz, D., Ihling, C. H., Stumvoll, M., Freire, R., Fiorentino, M., Fasano, A., Kovacs, P., & Heiker, J. T. (2018). Widely used commercial ELISA does not detect precursor of haptoglobin2, but recognizes properdin as a potential second member of the zonulin family. Frontiers in Endocrinology, 9, 22. https://doi.org/10.3389/fendo.2018.00022
    • Zhou, Q., Verne, M. L., Fields, J. Z., Lefante, J. J., Basra, S., Salameh, H., & Verne, G. N. (2019). Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome. Gut, 68(6), 996-1002. https://doi.org/10.1136/gutjnl-2017-315136
    • Arribas-López, E., Zand, N., Ojo, O., Snowden, M. J., & Kochhar, T. (2021). The effect of amino acids on wound healing: A systematic review and meta-analysis on arginine and glutamine. Nutrients, 13(8), 2498. https://doi.org/10.3390/nu13082498
    • Mahmood, A., FitzGerald, A. J., Marchbank, T., Ntatsaki, E., Murray, D., Ghosh, S., & Playford, R. J. (2006). Zinc carnosine, a health food supplement that stabilises small bowel integrity and stimulates gut repair processes. Gut, 56(2), 168-175. https://doi.org/10.1136/gut.2006.099929
    • Tan, B., Luo, H.-Q., Xu, H., Lv, N.-H., Shi, R.-H., Luo, H.-S., Li, J.-S., Ren, J.-L., Zou, Y.-Y., Li, Y.-Q., Ji, F., Fang, J.-Y., & Qian, J.-M. (2017). Polaprezinc combined with clarithromycin-based triple therapy for Helicobacter pylori-associated gastritis: A prospective, multicenter, randomized clinical trial. PLoS One, 12(4), e0175625. https://doi.org/10.1371/journal.pone.0175625
    • Hepsomali, P., Groeger, J. A., Nishihira, J., & Scholey, A. (2020). Effects of oral gamma-aminobutyric acid (GABA) administration on stress and sleep in humans: A systematic review. Frontiers in Neuroscience, 14, 923. https://doi.org/10.3389/fnins.2020.00923
    • Hoilat, G. J., Altowairqi, A. K., Ayas, M. F., Alhaddab, N. T., Alnujaidi, R. A., Alharbi, H. A., Alyahyawi, N., Kamal, A., Alhabeeb, H., Albazee, E., Almustanyir, S., & Abu-Zaid, A. (2022). Larazotide acetate for treatment of celiac disease: A systematic review and meta-analysis of randomized controlled trials. Clinics and Research in Hepatology and Gastroenterology, 46(1), 101782. https://doi.org/10.1016/j.clinre.2021.101782
    • Wessells, K. R., & Brown, K. H. (2012). Estimating the global prevalence of zinc deficiency: Results based on zinc availability in national food supplies and the prevalence of stunting. PLoS One, 7(11), e50568. https://doi.org/10.1371/journal.pone.0050568
    • Raftery, T., Martineau, A. R., Greiller, C. L., Ghosh, S., McNamara, D., Bennett, K., Meddings, J., & O’Sullivan, M. (2015). Effects of vitamin D supplementation on intestinal permeability, cathelicidin and disease markers in Crohn’s disease: Results from a randomised double-blind placebo-controlled study. United European Gastroenterology Journal, 3(3), 294-302. https://doi.org/10.1177/2050640615572176

    Related reading

  • Dr. Gurpreet Singh Padda beside the title card reading The Liver Flush Is Soap, The Angry Gut, Chapter 28

    Postcholecystectomy Diarrhea: A Measurement-First Workup

    The Liver Flush Is Soap | The Angry Gut, Chapter 28

    Postcholecystectomy Diarrhea: A Measurement-First Workup

    The workup for postcholecystectomy diarrhea starts by identifying bile acid diarrhea through the bile acid assessment available via gastroenterology, before any empiric antibiotic for overgrowth, which needs a positive breath test as its trigger. A gallstone or cholecystectomy history also belongs in the selection criteria for cardiometabolic measurement.

    Patients with loose stools after cholecystectomy are often treated for overgrowth without a positive test. The evidence favors identifying bile acid loss first, and gallbladder disease itself is a cardiometabolic flag.

    Postcholecystectomy diarrhea is usually handled as a nuisance to live with or as small intestinal bacterial overgrowth treated on suspicion. Both responses skip a measurement. Chapter 28 of The Angry Gut, by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes, is summarized in the video above, The Liver Flush Is Soap, and is built around a patient given four antibiotic courses for overgrowth whose breath tests were negative each time. For a primary care or pain practice the practical content is a sequence: identify bile acid diarrhea, withhold empiric antibiotics that lack a trigger, and treat the gallbladder history as an indication for metabolic screening.

    How common is bile acid diarrhea in chronic diarrhea?

    At a single teaching hospital, 1,071 consecutive outpatients with chronic diarrhea were scanned, and 42.7% had bile acid diarrhea; prior cholecystectomy was one of three predictors of an abnormal result. Selection did not create the yield. Of all referrals, 61.0% carried no known risk factor, and 35.7% of that subgroup still tested positive. Positives were type II in 51.6%, type III in 36.1% and type I in 12.3%, and 33.9% were severe. Yield showed no downward trend over five years (p = 0.39) while referrals for terminal ileal Crohn’s disease or resection fell, which argues against looser ordering diluting the figure.

    One constraint applies in the United States: the scan used in that cohort is not available here, so the prevalence transfers and the diagnostic route does not. Referral to gastroenterology for the bile acid assessment available locally is the practical step. None of these investigations is a Measura test.

    Is SIBO common after cholecystectomy?

    The intuitive model holds that losing the reservoir lets bacteria ascend. Dr. Padda taught that model, and the cohorts forced a revision. In 146 abdominal surgery patients against 30 healthy controls, overgrowth ran 37.6% versus 13.3%, yet cholecystectomy had the lowest rate at 17.1%, against 36.0% after hysterectomy and 96.2% after gastrectomy; previous gastrectomy and elevated gastrin independently predicted the hydrogen pattern. Among 265 patients with gallbladder disease and 39 controls, positivity peaked in patients with stones in situ, 40.5%, and gallstones were the only independent factor.

    Two implications follow. Stasis with the organ present carries more risk than its absence, and gastrin points to failed acid control rather than lost bile after surgery. Empiric antibiotics for overgrowth need a positive test as their trigger, and repeating a course after negative breath tests treats an assumption. The pressure behind the habit is structural: a prescription can be written inside a short encounter, whereas a breath test requires patient preparation and another visit.

    Why is gallbladder disease a cardiometabolic finding?

    The same gallstone cohort found gallbladder disease independently associated with fatty liver and metabolic syndrome as well as overgrowth. A gallbladder that fails to empty travels with metabolic disease rather than standing alone as a mechanical fault. That makes a gallstone or cholecystectomy history a reasonable entry in selection criteria for cardiometabolic measurement, whatever the bowel complaint.

    Physiology supports the association. Luminal bile salts limit endotoxin absorption: in obstructive jaundice, oral deoxycholate given to 12 patients before surgery was followed by no systemic endotoxemia and no postoperative renal impairment. In the book’s frame the gut is the first brain and the skull holds the second brain, and endotoxin crossing a depleted luminal defense is one input to metaflammation. Maldigested fat and the fat-soluble vitamins lost with it add a nutritional dimension that routine follow-up seldom documents.

    Surrogates move while patients may not

    The bile literature is a lesson in endpoint discipline. A randomized trial of oral ursodeoxycholic acid in 40 jaundiced patients raised bile salt concentrations and lowered portal endotoxemia, yet systemic endotoxemia, renal function, morbidity and mortality were unchanged. Pooled trials of the same drug in primary biliary cholangitis lowered alkaline phosphatase by 257 U/L without reducing mortality, 45 of 699 against 46 of 692. In a two-year trial of 100 patients already on that drug with inadequate response, complete biochemical response in the placebo add-on arm was 0%, so non-response was visible in the blood work and identifiable in advance.

    Patients also arrive taking tauroursodeoxycholic acid. Its best metabolic data, in 20 obese adults at 1,750 mg daily for four weeks, showed roughly a 30% gain in hepatic and muscle insulin sensitivity with no gut or liver endpoint recorded. The workflow lesson is identical for prescriptions and supplements: record which value is expected to change and when it will be rechecked. Decisions to start, continue or stop any agent stay with the treating physician.

    What Measura adds, and what it does not

    Measura [Cardiometabolic and Autonomic Health Analysis] does not measure bile acids, gallbladder function, breath hydrogen or methane, or intestinal permeability; those belong to gastroenterology. It measures the terrain the gallstone data point toward:

    Findings return to the ordering physician, and reading them in clinical context is outlined in interpreting the report.

    Standing orders for postcholecystectomy diarrhea

    Criteria only hold when they run without anyone remembering them. A gallstone or cholecystectomy history, chronic diarrhea with prior empiric antibiotics, or known fatty liver can each trigger metabolic measurement through standing orders. Insulin resistance and body composition documented at the wellness visit give a baseline and a repeat interval, as described in annual wellness visit integration. The patient-facing version is bile acid malabsorption after gallbladder surgery; bile as a signaling molecule is covered in the bile mechanism post; barrier repair follows in intestinal permeability testing; and every study cited is set out with its limits in the Chapter 28 companion.

    Frequently asked questions

    Should diarrhea after cholecystectomy be treated empirically as SIBO?

    Not without a positive test. In surgical cohorts, overgrowth was least frequent after cholecystectomy, at 17.1%, and bile acid diarrhea was found in 42.7% of outpatients referred for chronic diarrhea, with prior cholecystectomy a predictor. Repeating antibiotics after negative breath tests adds exposure without a diagnosis. The broader case for measuring before managing is set out in clinical rationale.

    Is bile acid testing part of the Measura protocol?

    No. Bile acid assessment, gallbladder imaging and breath testing are gastroenterology investigations performed elsewhere. Measura measures the metabolic terrain that gallbladder disease travels with, through laboratory panels and body composition, and returns findings to the ordering physician. How those measures are used across practice types is described in specialty applications.

    Why screen patients with gallstones for metabolic disease?

    In 265 patients with gallbladder disease, the disease was independently associated with fatty liver and metabolic syndrome. A cholecystectomy or gallstone history is therefore a documented marker of metabolic risk that is already in the chart. Measuring insulin resistance and body composition converts that marker into a baseline with a repeat interval. Framing it as written criteria is covered in making screening reproducible.

    How should supplement use be handled when patients bring TUDCA or milk thistle?

    Document the agent and the value it is expected to change. Pooled milk thistle trials lowered AST and ALT but had no effect on alkaline phosphatase and none at a BMI of 30 or above; tauroursodeoxycholic acid trials measured insulin action and immune cells, not bile flow. No agent has been shown to raise measured bile flow in humans. Tracking values between visits is covered in chronic care and between-visit monitoring.

    How do these findings support quality documentation?

    Measured insulin resistance, body composition and a scheduled repeat interval are structured findings that document cardiometabolic risk assessment rather than leaving it implied by a gallbladder history. They also make change over time visible in the record. How cardiometabolic measurement maps to reporting programs is described in MIPS and quality reporting.

    Is diarrhea common after gallbladder removal?

    Chronic diarrhea after cholecystectomy is common enough to ask about. In 1,071 consecutive outpatients referred for chronic diarrhea, 42.7% had bile acid diarrhea, and prior cholecystectomy was one of three predictors of an abnormal result. A third of positives were severe. The practical step is to identify bile acid diarrhea rather than treat the complaint as a nuisance to live with or as presumed overgrowth.

    What causes diarrhea after cholecystectomy?

    The evidence favors looking for bile acid diarrhea first, ahead of bacterial overgrowth. In surgical cohorts, cholecystectomy carried the lowest overgrowth rate, 17.1%, against 96.2% after gastrectomy, and positivity peaked in patients whose stones were still in place. Stasis with the organ present carries more risk than its absence. Repeating antibiotics after negative breath tests treats an assumption rather than a diagnosis.

    How is bile acid diarrhea diagnosed in the United States?

    Through gastroenterology. The scan used in the 1,071-patient cohort is not available here, so its prevalence transfers but its diagnostic route does not. Referral for the bile acid assessment available locally is the practical step, ahead of any empiric antibiotic for overgrowth, which needs a positive breath test as its trigger. None of these investigations is a Measura test.

    Build metabolic screening into the workup

    Learn how the Measura protocol adds laboratory and body composition measurement for patients whose gallbladder history flags metabolic risk.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Lim, S. J., Gracie, D. J., Kane, J. S., Mumtaz, S., Scarsbrook, A. F., Chowdhury, F. U., Ford, A. C., & Black, C. J. (2019). Prevalence of, and predictors of, bile acid diarrhea in outpatients with chronic diarrhea: a follow-up study. Neurogastroenterology and Motility, 31(9), e13666. https://doi.org/10.1111/nmo.13666
    • Kim, Y. J., Paik, C. N., Jo, I. H., Kim, D. B., & Lee, J. M. (2021). Serum gastrin predicts hydrogen-producing small intestinal bacterial overgrowth in patients with abdominal surgery: a prospective study. Clinical and Translational Gastroenterology, 12(1), e00291. https://doi.org/10.14309/ctg.0000000000000291
    • Kim, D. B., Paik, C. N., Song, D. S., Kim, Y. J., & Lee, J. M. (2018). The characteristics of small intestinal bacterial overgrowth in patients with gallstone diseases. Journal of Gastroenterology and Hepatology, 33(8), 1477-1484. https://doi.org/10.1111/jgh.14113
    • Cahill, C. J., Pain, J. A., & Bailey, M. E. (1987). Bile salts, endotoxin and renal function in obstructive jaundice. Surgery, Gynecology & Obstetrics, 165(6), 519-522. https://pubmed.ncbi.nlm.nih.gov/3120329/
    • Thompson, J. N., Cohen, J., Blenkharn, J. I., McConnell, J. S., Barr, J., & Blumgart, L. H. (1986). A randomized clinical trial of oral ursodeoxycholic acid in obstructive jaundice. British Journal of Surgery, 73(8), 634-636. https://doi.org/10.1002/bjs.1800730819
    • Rudic, J. S., Poropat, G., Krstic, M. N., Bjelakovic, G., & Gluud, C. (2012). Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database of Systematic Reviews, 12(12), CD000551. https://doi.org/10.1002/14651858.CD000551.pub3
    • Corpechot, C., Chazouillères, O., Rousseau, A., Le Gruyer, A., Habersetzer, F., Mathurin, P., Goria, O., Potier, P., Minello, A., Silvain, C., Abergel, A., Debette-Gratien, M., Larrey, D., Roux, O., Bronowicki, J. P., Boursier, J., de Ledinghen, V., Heurgue-Berlot, A., Nguyen-Khac, E., … Poupon, R. (2018). A placebo-controlled trial of bezafibrate in primary biliary cholangitis. New England Journal of Medicine, 378(23), 2171-2181. https://doi.org/10.1056/NEJMoa1714519
    • Kars, M., Yang, L., Gregor, M. F., Mohammed, B. S., Pietka, T. A., Finck, B. N., Patterson, B. W., Horton, J. D., Mittendorfer, B., Hotamisligil, G. S., & Klein, S. (2010). Tauroursodeoxycholic acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes, 59(8), 1899-1905. https://doi.org/10.2337/db10-0308
    • Shahsavari, K., Ardekani, S. S., Ardekani, M. R. S., Esfahani, M. M., Kazemizadeh, H., Jamialahmadi, T., Iranshahi, M., Khanavi, M., & Hasanpour, M. (2025). Are alterations needed in Silybum marianum (Silymarin) administration practices? A novel outlook and meta-analysis on randomized trials targeting liver injury. BMC Complementary Medicine and Therapies, 25(1), 134. https://doi.org/10.1186/s12906-025-04886-y

    Related reading

  • Dr. Gurpreet Singh Padda beside the Chapter 27 title card of The Angry Gut reading The Weeds Were Never the Problem

    SIBO Recurrence Rate: Screening the Host After the Kill

    The Weeds Were Never the Problem | The Angry Gut, Chapter 27

    SIBO Recurrence Rate: Screening the Host After the Kill

    After breath tests normalized with rifaximin, SIBO recurred in 12.6% of patients at three months, 27.5% at six months and 43.7% at nine months. Those checkpoints make defensible recheck points, and chronic proton pump inhibitor use, which raised recurrence odds more than threefold, is the one predictor a practice can modify.

    Eradication succeeds often enough that recurrence gets treated as bad luck. The recurrence data describe a predictable curve, modifiable predictors and a gap between clearance and response that a follow-up plan should be built around.

    The SIBO recurrence rate is the number that should shape follow-up after eradication, and it is rarely discussed when the first course is prescribed. The video The Weeds Were Never the Problem, from The Angry Gut by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes, argues that antibiotic clearance without a plan for what repopulates the bowel produces a shortening cycle. The ruling it lands on is to judge the result on function. For a screening practice that raises concrete questions: when to recheck, which predictors to act on, what microbial testing cannot say, and which host measures document the patient rather than the organisms.

    The SIBO recurrence rate curve and its checkpoints

    In the recurrence cohort, patients whose breath test normalized after a week of rifaximin tested positive again in 12.6% at three months, 27.5% at six months and 43.7% at nine months, with symptoms rising in parallel with test positivity. Follow-up ended at nine months, so the second year is unmeasured. The retreatment trial in diarrhea-predominant IBS saw 44.1% respond to the open-label phase, and 692 of 1,074 responders, 64.4%, relapsed within eighteen weeks. Retreatment of responders beat placebo modestly, 38.1% against 31.5%, in a population preselected for having responded once.

    Those intervals give follow-up its structure. Three, six and nine months are where recurrence was actually measured, which makes them defensible recheck points and natural anchors for standing orders rather than waiting for symptoms to force a visit.

    Predictors that are not organisms

    Chronic proton pump inhibitor use raised the odds of recurrence more than threefold, prior appendectomy nearly sixfold, and each added year of age carried an odds ratio of 1.09 (95% CI 1.02-1.16). Of the three, only the acid suppression is modifiable, which puts deprescribing review squarely in the recurrence plan. The medication decision belongs to the prescribing clinician after weighing the original indication; the point is that it is reviewed deliberately rather than renewed by default.

    There is a structural reason the review rarely happens. A branded antibiotic course arrives with registration trials, packaging and detailing, while fermented food and medication reconciliation have no sponsor and no representative. The kill acquires a guideline line; repopulation acquires a shrug at discharge. Practices that want a different recurrence curve have to build the unglamorous half into workflow, because no one will market it to them.

    Clearance is not response

    Pooled across 32 studies and 1,331 patients, rifaximin eradication runs 70.8% by intention to treat and 72.9% per protocol, with adverse events at 4.6%. Heterogeneity sits at I2 87-91% across the pooled estimates, and the authors grade the underlying study quality as generally poor. Co-therapy was among three covariates independently associated with higher eradication, a signpost rather than a protocol. The decisive figure is different: among patients whose overgrowth was demonstrably cleared, only 67.7% improved symptomatically. A third leave with a normal test and persistent illness.

    That gap is why a normal breath test should not close the episode. Symptom trajectory and host function need their own documentation, recorded at the same checkpoints as the repeat breath test.

    What microbial testing cannot tell you

    Stool microbiome sequencing, breath testing and fecal calprotectin are different tests performed elsewhere. Measura [Cardiometabolic and Autonomic Health Analysis] does not offer them. Their limits matter for interpretation regardless of who runs them. In a capsule transplant trial in irritable bowel syndrome, fecal diversity rose while quality of life at three months favored placebo. In healthy adults, more than doubling fiber from 21.5 to 45.1 g per day left alpha diversity unchanged cohort-wide, while 6.3 servings a day of fermented food raised diversity and lowered 19 of 93 inflammatory serum proteins, although the primary outcome was not met. Membership is not function.

    The post-antibiotic literature explains why. After four days of meropenem, gentamicin and vancomycin in healthy young men, composition approached baseline within about six weeks, yet nine species present in every subject beforehand remained undetectable in most at 180 days, and resistance-gene carriers were selected during the refill. The best post-antibiotic probiotic study found capsule strains delayed native mucosal recovery compared with unaided reconstitution, while autologous stool restored it within days; it measured composition and transcriptome, not clinical end points.

    Host function as the follow-up record

    If the ruling is function, the record should measure the host. The first brain sits upstream of the second, and persistent metaflammation does not respect the boundary between them. Laboratory panels cover the metabolic and inflammatory picture that a gut-focused workup tends to omit. Bioimpedance body composition and indirect calorimetry document muscle and fat compartments and measured resting energy expenditure in patients whose intake has been restricted across months of symptoms. Heart rate variability records autonomic tone. None of these detects overgrowth, and none substitutes for a repeat breath test; they document how the patient is functioning at the same checkpoints.

    Operationally, that means a standing order triggered at the final antibiotic dose, host measures at baseline and at the recurrence checkpoints, and medication review folded into the annual wellness visit. The same measures support documentation for MIPS and quality reporting. Primary studies and their limits are in the book companion, and testing before treating covers the measurement that should precede the first course.

    Frequently asked questions

    What is the recurrence rate of SIBO after rifaximin?

    In the cohort whose breath tests normalized after rifaximin, the three-month positivity was 12.6%, rising to 27.5% by six months and 43.7% by nine, with symptoms tracking the test. In diarrhea-predominant irritable bowel syndrome, 64.4% of responders relapsed within eighteen weeks. Neither dataset extends beyond its follow-up window. Report interpretation for longitudinal measures is covered in interpreting the report.

    Which recurrence predictors can be modified?

    Chronic proton pump inhibitor use, which raised the odds more than threefold, is the only modifiable one. Prior appendectomy raised them nearly sixfold and age carried an odds ratio of 1.09 per year. Reviewing whether acid suppression remains indicated is a prescriber decision that belongs in a structured medication review rather than routine renewal. The deprescribing workflow is discussed in the polypharmacy screening view.

    Does a negative breath test mean the patient has recovered?

    Not reliably. Among patients with demonstrated clearance, only 67.7% improved symptomatically, so roughly a third hold a normal test with persistent illness. Symptom trajectory and host function should be documented separately at the same checkpoints rather than inferred from organism counts. What changes for the patient describes how functional findings translate into management.

    Should stool microbiome testing guide repopulation?

    Diversity is a weak surrogate: fecal diversity climbed in one transplant trial even as placebo won on quality of life, and doubling fiber left diversity unchanged. Stool sequencing is performed elsewhere and is not a Measura test. Symptom intervals, repeat breath testing where indicated and host function measures are more decision-relevant. Selection logic for which measures to order sits under selection criteria.

    Where does fecal microbiota transplantation fit?

    It is established for recurrent Clostridioides difficile infection, where a single donor infusion cleared 13 of 16 patients while vancomycin alone cleared 4 of 13; pooled controlled trials give 73% against 84% in open-label series. FDA safety communications describe transmitted resistant and pathogenic infections, including deaths. Outside that indication trials conflict. The patient-facing account is written for the person after the course.

    Build host measures into eradication follow-up

    Learn how Measura laboratory, body composition, metabolic rate and autonomic measures fit standing orders timed to the recurrence checkpoints.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Lauritano, E. C., Gabrielli, M., Scarpellini, E., Lupascu, A., Novi, M., Sottili, S., Vitale, G., Cesario, V., Serricchio, M., Cammarota, G., Gasbarrini, G., & Gasbarrini, A. (2008). Small intestinal bacterial overgrowth recurrence after antibiotic therapy. The American Journal of Gastroenterology, 103(8), 2031-5. https://doi.org/10.1111/j.1572-0241.2008.02030.x
    • Lembo, A., Pimentel, M., Rao, S. S., Schoenfeld, P., Cash, B., Weinstock, L. B., Paterson, C., Bortey, E., & Forbes, W. P. (2016). Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology, 151(6), 1113-1121. https://doi.org/10.1053/j.gastro.2016.08.003
    • Gatta, L., & Scarpignato, C. (2017). Systematic review with meta-analysis: Rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Alimentary Pharmacology & Therapeutics, 45(5), 604-616. https://doi.org/10.1111/apt.13928
    • Halkjær, S. I., Christensen, A. H., Lo, B. Z. S., Browne, P. D., Günther, S., Hansen, L. H., & Petersen, A. M. (2018). Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study. Gut, 67(12), 2107-2115. https://doi.org/10.1136/gutjnl-2018-316434
    • Wastyk, H. C., Fragiadakis, G. K., Perelman, D., Dahan, D., Merrill, B. D., Yu, F. B., Topf, M., Gonzalez, C. G., Van Treuren, W., Han, S., Robinson, J. L., Elias, J. E., Sonnenburg, E. D., Gardner, C. D., & Sonnenburg, J. L. (2021). Gut-microbiota-targeted diets modulate human immune status. Cell, 184(16), 4137-4153.e14. https://doi.org/10.1016/j.cell.2021.06.019
    • Palleja, A., Mikkelsen, K. H., Forslund, S. K., Kashani, A., Allin, K. H., Nielsen, T., Hansen, T. H., Liang, S., Feng, Q., Zhang, C., Pyl, P. T., Coelho, L. P., Yang, H., Wang, J., Typas, A., Nielsen, M. F., Nielsen, H. B., Bork, P., Wang, J., … Pedersen, O. (2018). Recovery of gut microbiota of healthy adults following antibiotic exposure. Nature Microbiology, 3(11), 1255-1265. https://doi.org/10.1038/s41564-018-0257-9
    • Suez, J., Zmora, N., Zilberman-Schapira, G., Mor, U., Dori-Bachash, M., Bashiardes, S., Zur, M., Regev-Lehavi, D., Ben-Zeev Brik, R., Federici, S., Horn, M., Cohen, Y., Moor, A. E., Zeevi, D., Korem, T., Kotler, E., Harmelin, A., Itzkovitz, S., Maharshak, N., … Elinav, E. (2018). Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT. Cell, 174(6), 1406-1423.e16. https://doi.org/10.1016/j.cell.2018.08.047
    • Tariq, R., Pardi, D. S., & Khanna, S. (2023). Resolution rates in clinical trials for microbiota restoration for recurrent Clostridioides difficile infection: an updated systematic review and meta-analysis. Therapeutic Advances in Gastroenterology, 16, 17562848231174293. https://doi.org/10.1177/17562848231174293

    Related reading

  • Dr. Gurpreet Singh Padda beside the Chapter 26 title card of The Angry Gut reading Mold Illness: Fix the Basement, Skip the Panel

    CIRS Diagnosis: What the Mold Evidence Supports in Screening

    Mold Illness: Fix the Basement, Skip the Panel | The Angry Gut, Chapter 26

    CIRS Diagnosis: What the Mold Evidence Supports in Screening

    No assay in the CIRS diagnosis framework has a published healthy reference interval standardized across laboratories, so the panel cannot yet be read. What the mold evidence supports is immunologic and infectious disease, with the respiratory effects of damp buildings graded sufficient.

    Patients now arrive with a water-damaged building, a stalled recovery and a commercial result in hand. The clinical work is separating the established tiers from the marketed ones, then documenting function objectively.

    Requests for a CIRS diagnosis, chronic inflammatory response syndrome attributed to water-damaged buildings, now reach primary care, pain, gastroenterology and allergy clinics, usually after an adherent patient has improved partway and plateaued. The video Mold Illness: Fix the Basement, Skip the Panel, from The Angry Gut by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes, grades the mold literature by evidence tier. For a screening practice the questions are operational: which parts of the framework hold, which assays cannot be interpreted, what belongs in the chart, and where objective function measurement earns a place.

    What is established, and at which tier

    The mold-related disease with defined mechanisms is immunologic and infectious: asthma, allergic rhinitis, allergic bronchopulmonary aspergillosis, sinusitis and hypersensitivity pneumonitis. The allergy position paper that set out those mechanisms classed the newer proposed syndromes as largely unproved. The 2004 Institute of Medicine synthesis found sufficient evidence associating damp indoor environments with some upper respiratory symptoms, and American medical toxicology still endorses it. A 2024 multi-society European guideline grades respiratory disease as sufficient, atopic eczema as limited or suspected, and gastrointestinal effects as inadequate or insufficient.

    Exposure route is the skeptics’ strongest argument, and it is arithmetic rather than rhetoric. The 2025 American College of Medical Toxicology statement identifies diet as the most important source of human mycotoxin exposure and cites modeling that places the maximum inhaled dose in moldy buildings orders of magnitude below demonstrated thresholds for harm. The same statement reports no documented evidence that indoor fungal or mycotoxin inhalation causes a chronic toxic encephalopathy. Occupational medicine reached the equivalent conclusion in 2003.

    The CIRS diagnosis panel, and why it cannot yet be read

    Measura [Cardiometabolic and Autonomic Health Analysis] performs none of the framework’s assays: no mycotoxin or mycotoxin antibody testing, no urine toxin panels, no HLA-DR/DQ typing, no alpha-MSH, TGF-beta 1, C4a or MMP-9 profile, and no visual contrast sensitivity testing. Those are different tests run elsewhere. The case definition itself is falsifiable, which is to its credit: reduced regulatory neuropeptides, especially MSH, with elevation of at least one of the three inflammatory markers. Outside the originating group it stands neither falsified nor confirmed.

    Alpha-MSH is a genuine anti-inflammatory peptide, but it does not behave like a deficiency marker. It rose in normal subjects given endotoxin, fell in sepsis, was elevated in more advanced HIV disease and in more inflamed synovial fluid, and runs lower in healthy elderly people than in young controls. No reference interval from a healthy population, assay standardization, inter-laboratory comparison or pre-analytic stability data has been published. Among the 28 who consented to the primary cholestyramine trial, 25 had an abnormal MSH and 1 an abnormal IgE, and MSH was not re-measured after treatment.

    Urine mycotoxin panels fail on the same missing distribution. There is no FDA-approved urine mycotoxin assay. The federal case report is instructive when each value is read against its own line: ochratoxin returned at 2.8 ppb against that analyte’s cutoff of 2.0 ppb, and trichothecenes at 0.4 ppb against a separate cutoff of 0.2 ppb. Both exceeded their thresholds; destructive testing of the building found no water damage or significant fungal growth. The agency does not recommend biologic testing of people who work or live in water-damaged buildings, and the toxicology statement adds that antibody testing is not an accepted exposure measure.

    The trial base, stated at its tier

    A 2024 review sympathetic to the framework found the Shoemaker Protocol described in 11 of the 13 articles it identified, with minimal peer-reviewed publication from other groups; the randomized base is two cholestyramine trials of 8 and 13 subjects. In the primary trial, 7 randomized to drug improved, 6 on placebo did not until they crossed over, and all relapsed on building reexposure without the drug. That rechallenge was unblinded, and no mycotoxin was measured in any participant, so the result speaks to a bile acid sequestrant rather than to demonstrated toxin clearance.

    The single independent replication compared 28 exposed individuals with 30 controls. The handheld contrast chart did not separate the groups; digital contrast sensitivity testing reached 100% sensitivity at 60-80% specificity. Exposure status was assigned from clinical signs with no exposure biomarker, which leaves circularity hard to exclude. Mechanism studies deserve their weight here without apology: trials exclude exactly the patient with polypharmacy, disrupted sleep and a flooded basement, so absence of a trial is a design fact, not a refutation.

    Where the evidence is strongest: removing the exposure

    The best controlled human data concern remediation. A Cochrane review pooling 12 studies and 8,028 participants found repairs reduced adult wheeze (odds ratio 0.64) and rhinitis (odds ratio 0.57), graded moderate quality, with no difference in children’s asthma days against information alone and no gut outcome in any included study. Occupational medicine and the European guideline, both skeptical of the diagnosis, hold that indoor mold growth should not be tolerated. The defensible plan is remediation, a period living away from the building, and dated symptom tracking.

    The drivers under a stalled patient usually stack three deep. Barrier injury at the gut wall, the first brain in the book’s frame, is supported by mycotoxin data from cell, tissue and animal models. Immune activation is established for the allergic and infectious syndromes. The third is structural: in a 1989 survey of 597 households, mold growth appeared in 45.9% of dwellings, and repair falls to whoever owns the building rather than whoever breathes in it.

    Documentation and where Measura fits

    Stress is not a finding; it records the point at which the workup ended. A defensible chart carries the exposure history with dates, the location-dependent symptom pattern, the non-mold causes excluded, and objective function measures that can be repeated after the building is repaired. That structure belongs in the annual wellness visit and in standing orders with explicit selection criteria rather than in an unvalidated assay.

    Measura’s role is host function, not exposure. Laboratory panels address alternative explanations for incomplete recovery, including the metabolic terrain and metaflammation. Cardiac autonomic reflex tests and heart rate variability quantify autonomic regulation when fatigue or orthostatic complaints dominate. Cognitive assessment documents cognition when concentration complaints are prominent and pairs with fall prevention workflows. None of these attributes a symptom to a building. Measured before remediation and repeated after, they turn the patient’s away-better observation into a documented n-of-1 comparison. The graded primary studies are in the book companion.

    Frequently asked questions

    Is there a validated laboratory test for CIRS?

    No assay in the framework has a published healthy reference interval with standardization across laboratories. Alpha-MSH moves with endotoxin, sepsis and age, and urine mycotoxin panels lack both FDA approval and population distributions. The European guideline states that no useful validated mycotoxin procedure exists for clinical diagnosis. Measura offers none of these assays. Principles for reading tests that do carry context are in interpreting the report.

    Should a patient from a water-damaged building have urine mycotoxin testing?

    Federal investigators do not recommend biologic testing of people who live or work in water-damaged buildings. Diet dominates human mycotoxin exposure, so low urinary levels are expected in healthy people, and a result above a laboratory-chosen cutoff does not establish inhaled exposure. If a result would not change management, it should not be ordered. Building inspection and repair carry the stronger evidence. Selection criteria frame what is worth ordering.

    Does cholestyramine treat mold-related illness?

    The randomized base is two small trials from one group, with no mycotoxin measured and an unblinded rechallenge. Cholestyramine binds bile acids, so symptom improvement does not show a toxin was bound. The strongest binder data are calcium montmorillonite trials in Ghanaians with dietary aflatoxin exposure, a different population and route. Medication decisions stay with the treating physician. The case for measuring before treating is in clinical rationale.

    Which objective measures help a stalled patient with a mold history?

    Measures of host function that can be repeated: laboratory panels for alternative explanations, autonomic testing when fatigue or orthostatic complaints dominate, and cognitive assessment when concentration is affected. None diagnoses mold illness. A baseline before remediation and a repeat afterward gives the chart a comparison in place of a label. Ordering and repeat intervals are covered under staffing and workflow.

    How should these complaints be documented for quality reporting?

    Record exposure history with dates, the symptom pattern by location, excluded alternatives, and objective measures with their repeat intervals, and avoid charting stress as a conclusion. Structured cognitive and functional status documentation supports annual wellness visit and quality measure elements without leaning on an uninterpretable panel. The patient-facing account of the same evidence is written for the person with the positive panel.

    See where function testing fits the workup

    Learn how Measura laboratory, autonomic and cognitive measures fit a standing-order workflow for stalled patients with a documented exposure history.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Bush, R. K., Portnoy, J. M., Saxon, A., Terr, A. I., & Wood, R. A. (2006). The medical effects of mold exposure. The Journal of Allergy and Clinical Immunology, 117(2), 326-333. https://doi.org/10.1016/j.jaci.2005.12.001
    • Leikin, J., Holland, M. G., Kurt, T. L., McKay, C. A., & Stolbach, A. I. (American College of Medical Toxicology). (2025). ACMT position statement: Medical toxicology considerations in the diagnosis and treatment of patients with concerns about mold-related inhalation exposures. https://www.acmt.net/wp-content/uploads/2025/08/PS_250813_ACMT-Position-Statement-Mold-Related-Inhalation-Exposures.pdf
    • Kawamoto, M., & Page, E. (2015). Notes from the field: Use of unvalidated urine mycotoxin tests for the clinical diagnosis of illness — United States, 2014. MMWR. Morbidity and Mortality Weekly Report, 64(6), 157-158. https://pubmed.ncbi.nlm.nih.gov/25695323/
    • Catania, A., Airaghi, L., Garofalo, L., Cutuli, M., & Lipton, J. M. (1998). The neuropeptide alpha-MSH in HIV infection and other disorders in humans. Annals of the New York Academy of Sciences, 840, 848-856. https://doi.org/10.1111/j.1749-6632.1998.tb09622.x
    • Dooley, M., Vukelic, A., & Jim, L. (2024). Chronic inflammatory response syndrome: a review of the evidence of clinical efficacy of treatment. Annals of Medicine and Surgery (2012), 86(12), 7248-7254. https://doi.org/10.1097/MS9.0000000000002718
    • Shoemaker, R. C., & House, D. E. (2006). Sick building syndrome (SBS) and exposure to water-damaged buildings: time series study, clinical trial and mechanisms. Neurotoxicology and Teratology, 28(5), 573-588. https://doi.org/10.1016/j.ntt.2006.07.003
    • Jimenez-Barbosa, I. A., Di Lizio, S., Ahn, S. B., Heng, B., Kim, J., Watson, A. J., & Khuu, S. K. (2026). Assessment of visual contrast sensitivity in biotoxin-exposed individuals using four testing methods. Annals of Medicine, 58(1), 2646821. https://doi.org/10.1080/07853890.2026.2646821
    • Sauni, R., Verbeek, J. H., Uitti, J., Jauhiainen, M., Kreiss, K., & Sigsgaard, T. (2015). Remediating buildings damaged by dampness and mould for preventing or reducing respiratory tract symptoms, infections and asthma. Cochrane Database of Systematic Reviews, 2015(2), CD007897. https://doi.org/10.1002/14651858.CD007897.pub3
    • Platt, S. D., Martin, C. J., Hunt, S. M., & Lewis, C. W. (1989). Damp housing, mould growth, and symptomatic health state. BMJ (Clinical Research Ed.), 298(6689), 1673-1678. https://doi.org/10.1136/bmj.298.6689.1673

    Related reading

  • Dr. Gurpreet Singh Padda presenting beside the title card Your Gut Bacteria Breathe Out Through Your Mouth, The Angry Gut, Chapter 25

    Intestinal Methanogen Overgrowth: A Measurement-First Workup

    Your Gut Bacteria Breathe Out Through Your Mouth | The Angry Gut, Chapter 25

    Intestinal Methanogen Overgrowth: A Measurement-First Workup

    Intestinal methanogen overgrowth is diagnosed by breath methane, not a stool census: under the North American Consensus, methane of at least 10 ppm at any point is positive. A single fasting value of 10 ppm or more reproduced the full two-hour result at 86.4% sensitivity and 100% specificity.

    Exhaled methane is one of the few gut measures that reads microbial activity rather than membership. Its criteria, its error bars and its metabolic company all shape how a primary care workup should run.

    Intestinal methanogen overgrowth is one of the few gut diagnoses anchored to a measure of microbial activity rather than a species inventory. Human cells produce no hydrogen or methane, so every molecule on a breath sample reflects fermentation in the patient that day. The practical position is blunt: the census is not the activity, and exhaled hydrogen and methane say more than culture or a commercial stool report. Breath testing is not part of the Measura library; it is ordered through gastroenterology or a reference laboratory. The video Your Gut Bacteria Breathe Out Through Your Mouth presents the argument, and the protocol, performance and workflow detail follow here.

    Why can’t a stool test diagnose methanogen overgrowth?

    When a European expert group sent one fecal specimen to six commercial microbiome services, diversity verdicts split three ways and the same genus was reported at 14.16% and 8.41%, labeled high at one laboratory and low at another. No service disclosed its reference cohort. The deeper problem survives better laboratories: paired DNA and RNA sequencing in adult men found only 81 of 182 prevalent pathways transcribed, and methanogenesis was encoded and transcribed solely by Methanobrevibacter, rare in DNA yet among the most heavily transcribed pathways. A census averages that signal away. Consensus authors also state that current small bowel culture techniques are not satisfactory for this assessment.

    I argued for the RNA readout myself, and it has a limit worth stating. Metatranscriptomic profiles vary within a person nearly as much as between people, so a single sample is durable for composition but not for activity. Breath methane is the activity measure that holds still.

    What are the breath test criteria for intestinal methanogen overgrowth?

    A breath result without substrate, dose, cutoff and timing is not a finding. The North American Consensus specifies lactulose 10 g or glucose 75 g for overgrowth; a hydrogen rise of at least 20 ppm from baseline by 90 minutes is positive, and methane of at least 10 ppm at any point is positive. Hydrogen, methane and carbon dioxide should be measured together, because methanogens consume four hydrogen molecules per methane molecule and can flatten the hydrogen curve. Before the consensus, thirteen case-control studies had used thirteen different methodologies.

    Two older conventions are gone. After reviewing more than 15,000 lactulose tests, the consensus ruled that a double peak has no validity, and it advised against using breath testing to estimate orocecal transit. Preparation calls for four weeks off antibiotics and an 8–12 hour fast; it is not necessary to stop proton pump inhibitors, and no position was reached on probiotics.

    The single fasting methane

    For methane specifically, the long protocol adds little. A single fasting value of at least 10 ppm reproduced the full two-hour result at 86.4% sensitivity and 100% specificity, correlated with stool Methanobrevibacter smithii load at R = 0.65, stayed stable for 14 weeks untreated and fell within two days of antibiotics. At 5 ppm and above, the fasting value predicted excessive methane production at 96.1% sensitivity and 99.7% specificity. Clinical association is consistent: breath methane and constipation carry an odds ratio of 3.51, and methane-predominant overgrowth has five times the likelihood of constipation of hydrogen-predominant disease. Severity separation is statistically real and clinically small, 5.65 against 4.32 on the constipation scale.

    How accurate is breath testing for overgrowth?

    Hydrogen-based criteria are where the error bars widen. In 139 symptomatic patients who had both duodenal aspirate culture and glucose breath testing, concordance was 65.5%, and breath sensitivity against culture was 42% with specificity 84%. Pooled case-control data show 35.5% positivity in irritable bowel syndrome and 29.7% in controls. Scintigraphy classified 48% of positive glucose tests as colonic fermentation. A center that adopted the consensus protocol saw positivity move from 29.7% to 39.5%, with the added positives arriving through methane criteria. The society update states that the definition lacks precision and that treatment after a positive test remains largely empiric.

    The best evidence that clearing methane changes symptoms is thin: 31 subjects in the intention-to-treat analysis, no true placebo arm, entry at methane above 3 ppm, and a post-hoc split of 15 patients. That is the evidence tier. A mediocre measurement of the right process still outperforms empiric treatment aimed at a name on a stool report.

    Sequencing the workup

    • Rule out overgrowth before lactose or fructose breath testing. In lactulose-positive irritable bowel syndrome, fructose positivity dropped from 62 to 3% once a week of antibiotics had been given.
    • Exclude inflammation early. In adults with irritable bowel symptoms, C-reactive protein of 0.5 or less or calprotectin of 40 µg/g or less leaves an inflammatory bowel disease probability of 1% or lower. Calprotectin does not detect overgrowth.
    • Consider fecal elastase-1 where maldigestion is plausible: 0.94 sensitivity and 0.69 specificity at 200 µg/g, with watery stool diluting the result.
    • Report which gases were measured. No consensus body has set a hydrogen sulfide threshold, so a sulfide cutoff is the laboratory’s own.

    The metabolic overlap Measura can measure

    Methane positivity keeps turning up in metabolically abnormal patients. In eleven prediabetic adults with obesity, mean BMI 35.17, and positive for methane, a 10-day neomycin and rifaximin course eliminated breath methane in eight, and in those eight LDL, total cholesterol and 120-minute insulin on glucose tolerance testing improved. Energy harvest did not change, stool methanogen counts did not fall significantly, and there was no control arm. It is a hypothesis, and it supports measuring the metabolic side rather than assuming it. The society update adds a laboratory signature: elevated folate with, less commonly, vitamin B12 deficiency.

    Measura [Cardiometabolic and Autonomic Health Analysis] contributes on that side, with results returned to the ordering physician:

    • Laboratory panels for insulin with glucose, lipids and nutritional markers in a methane-positive patient with prediabetes or obesity.
    • Bioimpedance body composition to separate lean and fat compartments where BMI is the only adiposity figure in the chart.

    There is also an incentive problem to name. Commercial stool kits are built around repeat purchase and colored dashboards, while a breath measure that settles the question generates nothing further to sell. That structure explains why patients arrive with folders of reports and no gas measurement. For practice design, see selection criteria and standing orders for screening; the metabolic case in pain populations is in why metabolic health belongs in a pain practice. The patient version is the methane breath test explained, and the full study limits are in the Angry Gut companion deep dive for Chapter 25.

    Frequently asked questions

    Is a single fasting methane sufficient to diagnose intestinal methanogen overgrowth?

    For methane, largely yes. Against the two-hour test as reference, a fasting value of at least 10 ppm showed 86.4% sensitivity with 100% specificity, and it correlated with stool Methanobrevibacter smithii load. Hydrogen and fructose or lactose questions still require the full substrate protocol. Interpretation remains with the ordering physician alongside symptoms and exclusion of inflammation. Review interpreting the report.

    Does Measura perform breath testing?

    No. Breath testing is not in the Measura library and is ordered through gastroenterology or a reference laboratory. Measura measures the metabolic, vascular, autonomic, body-composition and cognitive picture. In a methane-positive patient with prediabetes or obesity, that typically means insulin, lipids and body composition, returned to the ordering physician. See specialty applications.

    Why measure metabolic markers in a patient with methane-positive constipation?

    Because the two travel together in the available data. In a small single-arm study of prediabetic adults with obesity, clearing breath methane accompanied improvements in LDL, total cholesterol and late insulin on glucose tolerance testing, without a change in energy harvest. The design is weak, but a baseline metabolic panel is quick to add and documents the terrain. The same pairing of a gut or appetite finding with metabolic measurement is set out in food addiction screening.

    Can a stool microbiome report substitute for breath testing?

    No. One specimen sent to six commercial services returned conflicting diversity verdicts, with no disclosed reference cohort, and DNA profiles overstate what the community is transcribing. Stool consistency also shifts the major markers, including Methanobrevibacter. A census cannot report methanogen activity; exhaled methane can. Review the clinical rationale.

    How should breath and metabolic results be documented?

    Record the substrate, dose, gases measured and cutoffs with the breath result, since a value without its protocol cannot be interpreted later. File insulin, lipids and body composition as discrete values so they can be trended alongside symptom scores. Structured entry also supports longitudinal review at the annual wellness visit. See getting results into the record.

    How is intestinal methanogen overgrowth diagnosed?

    With a breath test, not a stool report. Under the North American Consensus, methane of at least 10 ppm at any point is positive, and hydrogen, methane and carbon dioxide are measured together because methanogens can flatten the hydrogen curve. Consensus authors state that current small bowel culture techniques are not satisfactory for this assessment. Breath testing is ordered through gastroenterology or a reference laboratory. The patient version is the methane breath test explained.

    What are the symptoms of intestinal methanogen overgrowth?

    Constipation is the consistent association. Breath methane and constipation carry an odds ratio of 3.51, and methane-predominant overgrowth has five times the likelihood of constipation of hydrogen-predominant disease. The severity difference is statistically real and clinically small, 5.65 against 4.32 on the constipation scale. Methane positivity also keeps turning up in metabolically abnormal patients, which is why the metabolic side deserves measurement.

    How is intestinal methanogen overgrowth treated?

    Treatment after a positive test remains largely empiric, and the choice belongs to the treating physician. In eleven methane-positive prediabetic adults with obesity, a 10-day neomycin and rifaximin course eliminated breath methane in eight, and in those eight LDL, total cholesterol and 120-minute insulin improved. There was no control arm. Measura does not treat; it measures the metabolic side and returns results to the ordering physician.

    See how metabolic testing fits a gut workup

    Learn how Measura laboratory panels and body composition testing can sit alongside breath testing in your practice’s workup of methane-positive patients.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Rezaie, A., Buresi, M., Lembo, A., Lin, H., McCallum, R., Rao, S., Schmulson, M., Valdovinos, M., Zakko, S., & Pimentel, M. (2017). Hydrogen and methane-based breath testing in gastrointestinal disorders: The North American Consensus. The American Journal of Gastroenterology, 112(5), 775-784. https://doi.org/10.1038/ajg.2017.46
    • Takakura, W., Pimentel, M., Rao, S., Villanueva-Millan, M. J., Chang, C., Morales, W., Sanchez, M., Torosyan, J., Rashid, M., Hosseini, A., Wang, J., Leite, G., Kowalewski, E., Mathur, R., & Rezaie, A. (2022). A single fasting exhaled methane level correlates with fecal methanogen load, clinical symptoms and accurately detects intestinal methanogen overgrowth. The American Journal of Gastroenterology, 117(3), 470-477. https://doi.org/10.14309/ajg.0000000000001607
    • Kunkel, D., Basseri, R. J., Makhani, M. D., Chong, K., Chang, C., & Pimentel, M. (2011). Methane on breath testing is associated with constipation: A systematic review and meta-analysis. Digestive Diseases and Sciences, 56(6), 1612-8. https://doi.org/10.1007/s10620-011-1590-5
    • Erdogan, A., Rao, S. S. C., Gulley, D., Jacobs, C., Lee, Y. Y., & Badger, C. (2015). Small intestinal bacterial overgrowth: Duodenal aspiration vs glucose breath test. Neurogastroenterology and Motility, 27(4), 481-9. https://doi.org/10.1111/nmo.12516
    • Baker, J. R., Chey, W. D., Watts, L., Armstrong, M., Collins, K., Lee, A. A., Dupati, A., Menees, S., Saad, R. J., Harer, K., & Hasler, W. L. (2021). How the North American Consensus protocol affects the performance of glucose breath testing for bacterial overgrowth versus a traditional method. The American Journal of Gastroenterology, 116(4), 780-787. https://doi.org/10.14309/ajg.0000000000001110
    • Quigley, E. M. M., Murray, J. A., & Pimentel, M. (2020). AGA Clinical Practice Update on small intestinal bacterial overgrowth: Expert review. Gastroenterology, 159(4), 1526-1532. https://doi.org/10.1053/j.gastro.2020.06.090
    • Mathur, R., Chua, K. S., Mamelak, M., Morales, W., Barlow, G. M., Thomas, R., Stefanovski, D., Weitsman, S., Marsh, Z., Bergman, R. N., & Pimentel, M. (2016). Metabolic effects of eradicating breath methane using antibiotics in prediabetic subjects with obesity. Obesity (Silver Spring), 24(3), 576-82. https://doi.org/10.1002/oby.21385
    • Abu-Ali, G. S., Mehta, R. S., Lloyd-Price, J., Mallick, H., Branck, T., Ivey, K. L., Drew, D. A., DuLong, C., Rimm, E., Izard, J., Chan, A. T., & Huttenhower, C. (2018). Metatranscriptome of human faecal microbial communities in a cohort of adult men. Nature Microbiology, 3(3), 356-366. https://doi.org/10.1038/s41564-017-0084-4
    • Menees, S. B., Powell, C., Kurlander, J., Goel, A., & Chey, W. D. (2015). A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. The American Journal of Gastroenterology, 110(3), 444-54. https://doi.org/10.1038/ajg.2015.6
    • Pimentel, M., Chang, C., Chua, K. S., Mirocha, J., DiBaise, J., Rao, S., & Amichai, M. (2014). Antibiotic treatment of constipation-predominant irritable bowel syndrome. Digestive Diseases and Sciences, 59(6), 1278-85. https://doi.org/10.1007/s10620-014-3157-8

    Related reading

  • Dr. Gurpreet Singh Padda presenting beside the title card Your Sugar Craving Has a Schedule, The Angry Gut, Chapter 24

    Food Addiction Screening: What the Questionnaire Cannot Measure

    Your Sugar Craving Has a Schedule | The Angry Gut, Chapter 24

    Food Addiction Screening: What the Questionnaire Cannot Measure

    A positive craving questionnaire documents what a patient reports. It says nothing about insulin, energy expenditure or autonomic tone, and those are the variables a clinician can actually follow.

    Food addiction screening is scored with a self-report instrument, not a biomarker. Pooled across 272 studies, prevalence on the standard scale is 20%, and it reaches 55% in samples where binge eating is already diagnosed. Whether the construct is valid remains open; many defining features of drug addiction do not appear with food, even if the two share neural machinery. A positive screen therefore documents an experience accurately and a disease provisionally. For the clinician, the useful question is what sits underneath it that can be measured and followed. The video Your Sugar Craving Has a Schedule lays out the gut-to-brainstem route; the screening and workup implications follow.

    What does a food addiction screen measure, and who was it tested on?

    The pooled prevalence carries its own fine print. Clinical samples scored higher than community samples, as expected for a tool used inside eating-disorder programs. Age coverage is thin: two included studies enrolled only children, and none enrolled only older adults. A geriatric patient with a positive score is being compared against almost no one.

    In the cohort where the microbiome was sequenced alongside the scale, 19 of 105 women screened positive. Seventeen of those 19 had obesity, against 34 of the 86 who screened negative, and mean BMI ran 35.6 with the label against 29.1 without it. The instrument tracked adiposity more than anything else measured. Alpha diversity did not differ between the groups, which is worth knowing before a patient arrives with a direct-to-consumer stool report as supporting evidence.

    Why the framing changes management

    The distinction is clinical rather than semantic. If the pattern is addiction in the strict sense, management is abstinence and indefinite relapse prevention. If it is a preference written by exposure, management is changing the exposure and allowing time. The evidence favors the second model more than most clinicians expect.

    Normal-weight adults given a daily high-fat, high-sugar snack for eight weeks showed lower preference for low-fat food and greater neural response to food, with no relationship to body weight or metabolic parameters. Separately, inpatients offered ultra-processed and unprocessed diets matched on presented calories, energy density, macronutrients, sugar, sodium and fiber ate 508 kcal a day more on the ultra-processed arm, with the excess coming from carbohydrate and fat and protein intake flat. Weight change tracked intake at r = 0.8.

    I spent years delivering eat-less counseling to people whose appetite had been reshaped by the food supply, and I documented the failures as adherence problems. The snack trial is what reframed that for me: preference moved in people whose weight did not. The economic driver belongs in the same note. Refined carbohydrate is the cheapest calorie available because agricultural policy subsidized it, and it is formulated to succeed against the reward circuitry those trials measured.

    What does a food addiction questionnaire miss?

    A craving history is a reason to measure metabolic and autonomic state, not a substitute for it. Measura [Cardiometabolic and Autonomic Health Analysis] does not score food addiction, sequence stool or treat; it produces measurements that return to the ordering physician.

    • Insulin sensitivity. In 45 adults who were not habitual sweetener users, sucralose consumed with carbohydrate, but not sucralose alone, reduced insulin sensitivity over two weeks, and taste preference did not change. An adolescent arm was stopped after HOMA-IR rose above 12.9 in two of three participants. A history of sweetened beverages alongside starch justifies laboratory panels that pair insulin with glucose rather than glucose alone.
    • Measured energy expenditure. When intake is the clinical argument, indirect calorimetry replaces a predictive equation with the patient’s measured resting metabolic rate, which gives calorie counseling a denominator the patient cannot dispute.
    • Autonomic baseline. Heart rate variability reflects autonomic balance. It is not a readout of vagal gut signaling, and the vagus itself is a weak lever: in 239 patients randomized to reversible vagal blockade or sham, excess weight loss was 24.4% against 15.9% and both co-primary endpoints were missed. HRV documents the terrain those signals travel through.

    Who should be tested after a positive food addiction screen?

    The reasonable candidates are patients with a positive score and obesity, patients with a binge eating diagnosis, patients whose craving pattern is time-locked and carbohydrate-specific, and patients whose history includes daily sweetened drinks with starchy food. Most will already carry insulin resistance, a mood disorder, disrupted sleep or polypharmacy, which is precisely why no clean trial describes them. Mechanism is the operative evidence tier for this population, and it is sufficient to justify measurement. For context on the denominator, fewer than 7% of US adults are metabolically healthy on the tighter criteria applied to NHANES after 2021, down from fewer than 12.2% on NHANES 2009–2016. In our clinic the figure is under 3%, practice-reported figures from our own population, not trial outcomes, and individual results vary. Formal criteria are outlined in selection criteria.

    Reading craving outcomes when a GLP-1 agonist is on board

    Semaglutide supplies the strongest human evidence that a gut-derived signal changes food preference. In 72 adults with obesity over 20 weeks, ad libitum intake fell 35%, and after correction for body weight there was no evidence of delayed gastric emptying. At two years, sweet-food craving improvement did not persist while savory craving and craving control did. Craving scores improved in step with weight loss, the eating questionnaire went to a subgroup of 88 on drug and 86 on placebo, and multiplicity was not controlled. Craving response and weight change cannot be separated in that dataset. A pre-treatment metabolic and autonomic baseline gives an independent reference that does not move simply because weight does.

    Building it into existing workflow

    Craving history fits the dietary and functional review already present in the annual wellness visit. A standing protocol that triggers insulin, measured resting energy expenditure and heart rate variability after a positive screen makes the response reproducible across clinicians; the logic is laid out in making screening reproducible. Results filed as structured data support longitudinal tracking and quality reporting. The patient-facing explanation is in what causes sugar cravings, and the full study-by-study limits are in the Angry Gut companion deep dive for Chapter 24.

    Frequently asked questions

    Is food addiction a validated diagnosis?

    Not yet. It is defined by a self-report scale, pooled prevalence is 20%, and the field has no consensus that the construct is valid, since many hallmark features of drug addiction are absent with food. Treat a positive score as a documented experience that warrants metabolic measurement rather than as a diagnosis that dictates an abstinence model. Review the clinical rationale.

    Does a stool microbiome report add anything to a positive screen?

    Very little for decision-making. In the sequenced cohort of women, alpha diversity did not differ between those who screened positive and those who did not, and no human study has shown a defined microbial change causing a craving. The measurable questions in these patients are metabolic. The limits of commercial gut testing are covered in intestinal methanogen overgrowth.

    Which laboratory measures belong with a positive screen?

    Pair insulin with glucose. The sucralose trial found impaired insulin sensitivity only when sweetener arrived with carbohydrate, a change glucose alone may not reveal early. Add measured resting energy expenditure when intake is the counseling focus, and an autonomic baseline where the history suggests broader dysregulation. Interpretation conventions are described in interpreting the report.

    Should screening change once a patient starts a GLP-1 agonist?

    The screen remains useful, but its trajectory is confounded. In the two-year semaglutide data, craving improvement correlated with weight loss, and sweet craving gains faded by two years. A baseline drawn before therapy, repeated at intervals, separates metabolic change from appetite change. Follow-up cadence for that kind of tracking is covered in chronic care and between-visit monitoring.

    How do results reach the chart?

    Measura returns results to the ordering physician, who makes any diagnosis and decides management. Filing insulin, resting metabolic rate and heart rate variability as discrete values lets a practice trend them against the craving score over successive visits instead of relying on narrative notes. Integration options are described in getting results into the record.

    How do you stop food cravings?

    The evidence points to exposure more than willpower. Normal-weight adults given a daily high-fat, high-sugar snack for eight weeks came to like low-fat food less, with no relationship to body weight. If the pattern is a preference written by exposure rather than addiction in the strict sense, management is changing the exposure and allowing time, not abstinence and indefinite relapse prevention. The patient version is what causes sugar cravings.

    See how the protocol fits a craving workup

    Learn how Measura adds insulin, measured resting metabolic rate and heart rate variability to your practice’s response to a positive food addiction screen.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Praxedes, D. R. S., Silva-Júnior, A. E., Macena, M. L., Oliveira, A. D., Cardoso, K. S., Nunes, L. O., Monteiro, M. B., Melo, I. S. V., Gearhardt, A. N., & Bueno, N. B. (2022). Prevalence of food addiction determined by the Yale Food Addiction Scale and associated factors: a systematic review with meta-analysis. European Eating Disorders Review, 30(2), 85-95. https://doi.org/10.1002/erv.2878
    • Fletcher, P. C., & Kenny, P. J. (2018). Food addiction: a valid concept?. Neuropsychopharmacology, 43(13), 2506-2513. https://doi.org/10.1038/s41386-018-0203-9
    • Dong, T. S., Mayer, E. A., Osadchiy, V., Chang, C., Katzka, W., Lagishetty, V., Gonzalez, K., Kalani, A., Stains, J., Jacobs, J. P., Longo, V. D., & Gupta, A. (2020). A distinct brain-gut-microbiome profile exists for females with obesity and food addiction. Obesity, 28(8), 1477-1486. https://doi.org/10.1002/oby.22870
    • Edwin Thanarajah, S., DiFeliceantonio, A. G., Albus, K., Kuzmanovic, B., Rigoux, L., Iglesias, S., Hanßen, R., Schlamann, M., Cornely, O. A., Brüning, J. C., Tittgemeyer, M., & Small, D. M. (2023). Habitual daily intake of a sweet and fatty snack modulates reward processing in humans. Cell Metabolism, 35(4), 571-584.e6. https://doi.org/10.1016/j.cmet.2023.02.015
    • Hall, K. D., Ayuketah, A., Brychta, R., Cai, H., Cassimatis, T., Chen, K. Y., Chung, S. T., Costa, E., Courville, A., Darcey, V., Fletcher, L. A., Forde, C. G., Gharib, A. M., Guo, J., Howard, R., Joseph, P. V., McGehee, S., Ouwerkerk, R., Raisinger, K., … Zhou, M. (2019). Ultra-processed diets cause excess calorie intake and weight gain: an inpatient randomized controlled trial of ad libitum food intake. Cell Metabolism, 30(1), 67-77.e3. https://doi.org/10.1016/j.cmet.2019.05.008
    • Dalenberg, J. R., Patel, B. P., Denis, R., Veldhuizen, M. G., Nakamura, Y., Vinke, P. C., Luquet, S., & Small, D. M. (2020). Short-term consumption of sucralose with, but not without, carbohydrate impairs neural and metabolic sensitivity to sugar in humans. Cell Metabolism, 31(3), 493-502.e7. https://doi.org/10.1016/j.cmet.2020.01.014
    • Ikramuddin, S., Blackstone, R. P., Brancatisano, A., Toouli, J., Shah, S. N., Wolfe, B. M., Fujioka, K., Maher, J. W., Swain, J., Que, F. G., Morton, J. M., Leslie, D. B., Brancatisano, R., Kow, L., O’Rourke, R. W., Deveney, C., Takata, M., Miller, C. J., Knudson, M. B., … Billington, C. J. (2014). Effect of reversible intermittent intra-abdominal vagal nerve blockade on morbid obesity: the ReCharge randomized clinical trial. JAMA, 312(9), 915-922. https://doi.org/10.1001/jama.2014.10540
    • Friedrichsen, M., Breitschaft, A., Tadayon, S., Wizert, A., & Skovgaard, D. (2021). The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity & Metabolism, 23(3), 754-762. https://doi.org/10.1111/dom.14280
    • Wharton, S., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., & Garvey, W. T. (2023). Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5. Obesity, 31(3), 703-715. https://doi.org/10.1002/oby.23673

    Related reading

  • Dr. Gurpreet Singh Padda presenting beside the title card Bile Is a Hormone, Not Soap, The Angry Gut, Chapter 23

    Cholecystectomy Complications: The Cohort Nobody Re-Screens

    Bile Is a Hormone, Not Soap | The Angry Gut, Chapter 23

    Cholecystectomy Complications: The Cohort Nobody Re-Screens

    Bile acid diarrhea after gallbladder surgery is testable and treatable, yet 2.1% of patients are ever investigated for it. The cohort is easy to define and almost never measured.

    Cholecystectomy complications are counted at thirty days and then stop being counted. The one that surfaces months later is bile acid diarrhea, which has a measured mechanism, an available test and an effective treatment, and it is investigated in a small fraction of patients. The physiology is set out on video in Bile Is a Hormone, Not Soap, chapter 23 of The Angry Gut (Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes). The operational question for a practice is narrower: which post-surgical patients deserve a second look, what the ejection fraction can and cannot decide, and what is worth measuring in the cohort that arrives after the gallbladder is gone.

    The cholecystectomy complication that leaves the denominator

    A multicenter audit found that of 9,439 patients who underwent the operation, 202, or 2.1%, were ever investigated for postoperative diarrhea. Among those investigated, 62.8% met criteria for bile acid diarrhea, and the median interval from surgery to the scan was 672 days. Read the direction, not the rate: only patients a clinician already suspected were referred, there was no comparison group who kept their gallbladders, and the positive proportion therefore describes the quality of the suspicion.

    Prospective counting gives the cleaner estimate. Questionnaires before elective laparoscopic cholecystectomy and again at twelve months, against people coming through a health check, found new functional diarrhea in 6.6% against 0.2%, new dyspepsia in 14.8% against 6.9%, and new chronic abdominal pain in 11.9% against 4.4%. Most pre-existing symptoms improved; chronic diarrhea was the exception. The detail worth keeping is that somatization predicted the new dyspepsia and the new pain but not the new diarrhea, which is the finding that should slow down a functional label.

    Why does diarrhea follow gallbladder removal?

    The tidy story, that removing the tissue richest in FGF19 causes the diarrhea, was tested head-on and failed: gallbladder hormone content showed no correlation with bowel habit or stool consistency. What survives is delivery timing. After surgery bile acid synthesis rises at least two-fold and the diurnal peak of the hormone flattens, yet serum bile acids, cholesterol and triglycerides did not move in that work, which is exactly why a routine panel gives no hint of it. Bile arriving continuously into a bowel built for a postprandial bolus delivers more to the colon, where bile acids drive secretion.

    I ordered ejection fractions for years and treated the cutoff as physiology rather than protocol, which was my mistake to make and worth stating before correcting anyone else’s.

    Does the ejection fraction predict relief after gallbladder surgery?

    Across 60 healthy volunteers at four centers, the lower limit of normal for the stimulated ejection fraction came out at 38%, and reproducibility depended entirely on the infusion: a coefficient of variation of 19% with the 60-minute infusion, and 52% with the short infusion in common use. In 93 consecutive patients with documented dyskinesia, the stimulated fraction was statistically indistinguishable between those who improved after surgery and those who did not. What predicted relief was the symptom pattern, with classic biliary pain 22 times more likely to be relieved. The operation is the right answer for a real biliary indication; the failure mode is the atypical patient selected on a number that cannot separate the two.

    The terrain that arrives with the patient

    In a population cohort of 4,307 people, metabolic syndrome ran 67.2% among those who had lost a gallbladder against 51.9% among those who had not, and moderate-to-severe fatty liver 42.7% against 34.2%, with imaging a median of ten years after surgery. Adjustment for metabolic factors removed both associations. That result is usually read as exoneration of the operation; the more useful reading for a practice is that this cohort was metabolically sick before the surgeon met them. Gallstones grow in bile made under hyperinsulinemia and stored in a reservoir rarely asked to empty, so the stone is a marker of the terrain and the surgery leaves the terrain in place. A cohort can adjust that away. A clinic cannot, because it walks in with the patient, and metaflammation in the first brain does not resolve because an organ was removed.

    What is not a Measura test, and what is

    Measura [Cardiometabolic and Autonomic Health Analysis] does not perform bile acid retention testing, gallbladder ultrasound, cholescintigraphy or breath testing, and it does not diagnose. Retention scanning is not licensed in the United States, which in practice leaves a supervised therapeutic trial with a defined endpoint and stop date as the usual route, decided by the treating clinician or gastroenterologist. What the protocol contributes is the metabolic and functional measurement this cohort almost never receives:

    • Laboratory panels characterize glycemic and lipid status and liver markers, which is the terrain that produced the stone and predicts the next decade.
    • Bioimpedance body composition separates lean from fat mass in patients who have been avoiding fat and losing muscle, which redirects counseling toward protein and loading.
    • Indirect calorimetry replaces a predicted resting expenditure with a measured one before any dietary target is set.
    • Where postprandial symptoms coexist with dizziness or presyncope, autonomic nervous system testing documents the regulatory response instead of leaving it described.

    Standing orders and documentation

    This cohort is easy to define, which makes it easy to protocolize. A standing order can attach a bowel-habit review and cardiometabolic measurement to any patient with a prior cholecystectomy and new or persistent loose stools, so the second look does not depend on who is in the room. The metabolic findings sit naturally in the annual wellness visit and support the measures set out in HEDIS and value-based care, while discrete results in the chart, rather than a scanned summary, are what make repeat measurement usable; see getting results into the record. Selection thresholds for the wider protocol are in the selection criteria.

    The full evidence file, including the null results that constrain the mechanism, is in the book companion for The Angry Gut. The patient explanation is what bile actually does.

    Frequently asked questions

    Which post-cholecystectomy patients warrant investigation for bile acid diarrhea?

    Those with loose or urgent stools that began after the operation and persist, particularly when fatty meals trigger them and structural workup is unremarkable. Prospective data put new functional diarrhea at 6.6% against 0.2% in controls at twelve months, and somatization did not predict it, so a functional label without testing is premature. Read the clinical rationale.

    Does a low ejection fraction justify cholecystectomy in an atypical patient?

    The evidence does not support deciding on that number alone. Stimulated fractions were indistinguishable between surgical responders and non-responders, while classic biliary pain was 22 times more likely to be relieved. Reproducibility also depends on infusion method, with a coefficient of variation of 19% or 52% depending on protocol. See guidance on interpreting the report.

    Can Measura testing replace bile acid or gallbladder testing?

    No. Retention scanning, cholescintigraphy, ultrasound and breath testing are separate investigations arranged through gastroenterology or radiology. The protocol measures the cardiometabolic, autonomic and body-composition picture, which is the part of this cohort’s risk that routinely goes undocumented, and results return to the ordering clinician. See more physician questions.

    Is the metabolic association with cholecystectomy causal?

    Probably not as a direct effect. In 4,307 people, metabolic syndrome ran 67.2% against 51.9% and fatty liver 42.7% against 34.2%, but adjustment for metabolic factors removed both. The practical inference is selection rather than causation: patients who form stones carry the metabolic terrain that produced them, which makes them a screening population. Read about specialty applications.

    How does this fit an existing primary care workflow?

    As a trigger attached to an existing cohort rather than a new clinic. Prior cholecystectomy plus persistent loose stools prompts a bowel-habit review, referral for the relevant gastroenterology testing, and cardiometabolic measurement in parallel. Staffing and supervision requirements for in-office testing are documented separately. Review staffing and workflow.

    What are the long-term side effects of cholecystectomy?

    In a prospective study that surveyed patients before elective laparoscopic cholecystectomy and again at twelve months, new functional diarrhea appeared in 6.6% against 0.2% of health-check controls, new dyspepsia in 14.8% against 6.9%, and new chronic abdominal pain in 11.9% against 4.4%. Most symptoms present before surgery improved. Chronic diarrhea was the exception, and it is the one worth testing.

    Is it normal to have stomach issues a year after gallbladder removal?

    Common is not the same as normal, and the late complication worth testing for is bile acid diarrhea. In one multicenter audit the median interval from surgery to the diagnostic scan was 672 days, and 62.8% of the patients investigated met criteria. Loose or urgent stools that began after the operation and persist, especially after fatty meals, call for a bowel-habit review rather than a functional label.

    Re-screen the post-surgical cohort

    Learn how the Measura protocol adds cardiometabolic, body composition and autonomic measurement to patients already carrying a post-cholecystectomy history.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Farrugia, A., Attard, J. A., Hanmer, S., Bullock, S., McKay, S., Al-Azzawi, M., Ali, R., Bond-Smith, G., Colleypriest, B., Dyer, S., Masterman, B., Okocha, M., Osborne, A., Patel, R., Sallam, M., Selveraj, E., Shalaby, S., Sun, W., Todd, F., … Arasaradnam, R. P. (2021). Rates of bile acid diarrhoea after cholecystectomy: A multicentre audit. World Journal of Surgery, 45(8), 2447-2453. https://doi.org/10.1007/s00268-021-06147-8
    • Chang, J. Y., Jung, H.-K., Moon, C. M., Kim, S.-E., Shim, K.-N., Jung, S.-A., & Min, S. K. (2023). Development of functional gastrointestinal disorder symptoms following laparoscopic cholecystectomy: A prospective cohort study. Frontiers in Medicine, 10, 1248465. https://doi.org/10.3389/fmed.2023.1248465
    • Farrugia, A., Williams, N., Khan, S., & Arasaradnam, R. P. (2024). Bile acid diarrhoea and metabolic changes after cholecystectomy: A prospective case-control study. BMC Gastroenterology, 24(1), 282. https://doi.org/10.1186/s12876-024-03368-8
    • Barrera, F., Azócar, L., Molina, H., Schalper, K. A., Ocares, M., Liberona, J., Villarroel, L., Pimentel, F., Pérez-Ayuso, R. M., Nervi, F., Groen, A. K., & Miquel, J. F. (2015). Effect of cholecystectomy on bile acid synthesis and circulating levels of fibroblast growth factor 19. Annals of Hepatology, 14(5), 710-721. https://pubmed.ncbi.nlm.nih.gov/26256900/
    • Ziessman, H. A., Tulchinsky, M., Lavely, W. C., Gaughan, J. P., Allen, T. W., Maru, A., Parkman, H. P., & Maurer, A. H. (2010). Sincalide-stimulated cholescintigraphy: A multicenter investigation to determine optimal infusion methodology and gallbladder ejection fraction normal values. Journal of Nuclear Medicine, 51(2), 277-281. https://doi.org/10.2967/jnumed.109.069393
    • Carr, J. A., Walls, J., Bryan, L. J., & Snider, D. L. (2009). The treatment of gallbladder dyskinesia based upon symptoms: Results of a 2-year, prospective, nonrandomized, concurrent cohort study. Surgical Laparoscopy, Endoscopy & Percutaneous Techniques, 19(3), 222-226. https://doi.org/10.1097/SLE.0b013e3181a74690
    • Latenstein, C. S. S., Alferink, L. J. M., Darwish Murad, S., Drenth, J. P. H., van Laarhoven, C. J. H. M., & de Reuver, P. R. (2020). The association between cholecystectomy, metabolic syndrome, and nonalcoholic fatty liver disease: A population-based study. Clinical and Translational Gastroenterology, 11(4), e00170. https://doi.org/10.14309/ctg.0000000000000170
    • Wedlake, L., A’Hern, R., Russell, D., Thomas, K., Walters, J. R. F., & Andreyev, H. J. N. (2009). Systematic review: The prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Alimentary Pharmacology & Therapeutics, 30(7), 707-717. https://doi.org/10.1111/j.1365-2036.2009.04081.x

    Related reading

  • Dr. Gurpreet Singh Padda presenting beside the title card The Antibiotic on Your Salad, The Angry Gut, Chapter 22

    Pesticide Exposure Testing: What to Measure When You Cannot

    The Antibiotic on Your Salad | The Angry Gut, Chapter 22

    Pesticide Exposure Testing: What to Measure When You Cannot

    Pesticide exposure testing has no validated endpoint for gut effects, and a spot urine level reports the last meal rather than the decade. Measure the terrain instead: laboratory panels, bioimpedance body composition, indirect calorimetry and sudomotor testing each carry a management decision.

    Patients ask for a residue test that does not exist. The mechanism is measured, the human endpoint is not, and the screening opportunity sits in the metabolic and autonomic terrain the patient brought with them.

    A patient who has read about herbicide residue arrives asking for pesticide exposure testing, and there is no panel that answers her question. No validated method exists for the endpoint she cares about, the effect of a dietary residue on her gut community, and a spot urine level reports her last meal rather than her decade. The mechanistic case is laid out on video in The Antibiotic on Your Salad, chapter 22 of The Angry Gut (Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes). What follows is the screening question: what to tell her, whom to test, and which measurements change management.

    What the mechanism claim is, and what it is not

    Glyphosate inhibits a single enzyme in the shikimate pathway. Human cells lack the pathway entirely, which is the basis of the human safety assessment and is correct as far as it goes. Bacteria do not lack it. A structural classification of the enzyme, run over thousands of organisms, assigned 54% of core gut species to the vulnerable form, a proportion its authors flagged as conservative. The counter-analysis matters equally: an expression-based census of reference genomes covering most assigned microbial abundance in human fecal metagenomes found the pathway largely incomplete and largely silent, with some organisms possibly degrading the compound rather than being inhibited by it.

    The animal work is where the argument has teeth. Rats dosed for ninety days at the European acceptable daily intake accumulated shikimic acid and its dehydro form in the cecum, a substrate pile-up behind the target enzyme in a living mammal at a regulated dose, with no reflection of those cecal metabolites in serum. A mouse study at roughly the American intake reported altered microbiota with inflammatory markers. The European peer review addressed the microbiome question directly and concluded that without standardized regulatory guidance or harmonized criteria, no definitive conclusion can be drawn from the available studies. That is the honest state of it: a measured mechanism, an unmeasured endpoint in people.

    Why is there no pesticide exposure test to order?

    Three reasons worth having at hand in the room. First, no study relates measured exposure to gut community composition in a human being, so a result would have no interpretive frame. Second, urinary levels are dominated by recent intake: levels were significantly lower in people who had fasted more than eight hours, in the same national sample of 2,310 specimens where 81.2% of Americans aged six and older tested positive. Third, exposure is to a formulation rather than the molecule, and commercial formulations were more cytotoxic than their active ingredients against human cells, while co-formulant identity is treated as confidential and is often described incorrectly in published work. A test of the pure compound, even if it existed, would be answering a question the patient is not living in.

    Who to test, and on what trigger

    The productive move is to stop chasing the exposure and start measuring the terrain the patient actually presents with. Reasonable triggers for cardiometabolic and autonomic measurement in this population:

    • Unexplained bowel symptoms lasting months with a normal structural workup, particularly alongside central adiposity, hypertension or a family history of type 2 diabetes.
    • A recent rebuilding window: repeated antibiotic courses, abdominal surgery or an inpatient stay in the preceding year.
    • Distal sensory symptoms accompanying the bowel complaint, where small-fiber function has never been documented.
    • Patients already committed to dietary change, who need a baseline rather than a lecture, as set out in the selection criteria.

    The rebuilding window is the part I would defend hardest, and it is a mechanistic argument rather than a trial result. An expression census describes a settled community at steady state. It does not describe recolonization, when a depleted community must synthesize aromatic amino acids instead of scavenging them. Patients arriving in your office after antibiotics or surgery are living in exactly that interval.

    What each finding changes

    Measura [Cardiometabolic and Autonomic Health Analysis] holds no residue assay, no urine herbicide level and no stool sequencing, and it does not diagnose. What it returns to the ordering clinician is the measurable terrain, and each result carries a decision with it.

    Documentation and workflow

    An exposure conversation that ends in measurement is easier to run from a protocol than from improvisation. A standing order can attach laboratory, body composition and small-fiber testing to a defined trigger, so the request does not depend on which clinician is in the room. Metabolic and functional findings belong in the annual wellness visit record, where they support the quality measures described under MIPS and quality reporting. Discrete results in the chart, rather than a scanned report, are what make repeat measurement interpretable; see getting results into the record.

    How to answer the question in clinic

    Say the three things that are true and stop. The compound’s entire mechanism is inhibition of an enzyme her bacteria carry and her cells do not. At an accepted dose that enzyme was measurably blocked in the gut of a mammal, and the fingerprint never reached blood, which is where the toxicology package looked. The human study pairing exposure with gut composition has not been run, and its entry criteria would exclude the patient asking. Then offer what is measurable. Declining to test for something is not the same as declining to investigate, and patients can tell the difference.

    The full evidence file with the counter-case stated at full strength sits in the book companion for The Angry Gut. The patient-facing explanation is what can actually be measured in you.

    Frequently asked questions

    Is there a way to test a patient for pesticide exposure?

    Not for the question patients ask. Urinary glyphosate is measurable in research settings but reflects intake within roughly a day, and no reference frame links a level to gut community composition or symptoms. The European peer review states that harmonized criteria for microbiome assessment do not exist, so studies cannot be pooled into a conclusion. Read the clinical rationale.

    How strong is the 54% sensitivity figure?

    It is a computational classification of the target enzyme across species, not a measurement of killing in a gut. The same tool classifies a large share of prokaryote sequences, and its predictions failed in both directions in a live bumblebee experiment. Treat it as a hypothesis with a defined mechanism, and say so to patients who have seen it quoted as settled. See guidance on interpreting the report.

    Should patients be discouraged from buying microbiome or residue panels?

    They should be told what the result can support. A stool sequencing report cannot attribute an organism to a dietary residue, and a single urine level describes the previous day. Redirect toward measurements with reference ranges and a management consequence, and document that the exposure question was raised and addressed. Review what a test result can and cannot tell you.

    Which patients gain most from measuring the terrain instead?

    Those with months of unexplained bowel symptoms plus metabolic risk, those within a year of antibiotics, abdominal surgery or hospitalization, and those with coexisting distal sensory complaints. In each case the finding changes something concrete: protein and loading targets, a measured energy prescription, or a documented small-fiber abnormality. Read about specialty applications.

    Does the formulation argument change clinical advice?

    It changes the confidence of reassurance, not the plan. Formulations were more cytotoxic than active ingredients against human cells, and co-formulant composition is confidential, so testing the pure compound answers a different question than the one eaten. Advise reducing residue on raw produce as an unquantified measure, and measure what can be measured. See what changes for the patient.

    How common is glyphosate in a patient’s urine?

    Close to universal. In a national sample of 2,310 urine specimens, 81.2% of Americans aged six and older had a detectable level. Levels were significantly lower in people who had fasted more than eight hours, which shows how heavily a result depends on the last meal. A positive result therefore separates almost no one from the population, and nothing links the level to gut community composition.

    Turn an exposure question into a measurement

    See how the Measura protocol fits laboratory, body composition, resting metabolism and small-fiber testing into an existing primary care workflow.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Leino, L., Tall, T., Helander, M., Saloniemi, I., Saikkonen, K., Ruuskanen, S., & Puigbò, P. (2021). Classification of the glyphosate target enzyme (5-enolpyruvylshikimate-3-phosphate synthase) for assessing sensitivity of organisms to the herbicide. Journal of Hazardous Materials, 408, 124556. https://doi.org/10.1016/j.jhazmat.2020.124556
    • Mesnage, R., & Antoniou, M. N. (2020). Computational modelling provides insight into the effects of glyphosate on the shikimate pathway in the human gut microbiome. Current Research in Toxicology, 1, 25-33. https://doi.org/10.1016/j.crtox.2020.04.001
    • Mesnage, R., Teixeira, M., Mandrioli, D., Falcioni, L., Ducarmon, Q. R., Zwittink, R. D., Mazzacuva, F., Caldwell, A., Halket, J., Amiel, C., Panoff, J.-M., Belpoggi, F., & Antoniou, M. N. (2021). Use of shotgun metagenomics and metabolomics to evaluate the impact of glyphosate or Roundup MON 52276 on the gut microbiota and serum metabolome of Sprague-Dawley rats. Environmental Health Perspectives, 129(1), 17005. https://doi.org/10.1289/EHP6990
    • Ospina, M., Schütze, A., Morales-Agudelo, P., Vidal, M., Wong, L.-Y., & Calafat, A. M. (2022). Exposure to glyphosate in the United States: Data from the 2013-2014 National Health and Nutrition Examination Survey. Environment International, 170, 107620. https://doi.org/10.1016/j.envint.2022.107620
    • Ferguson, S., Mesnage, R., & Antoniou, M. N. (2022). Cytotoxicity mechanisms of eight major herbicide active ingredients in comparison to their commercial formulations. Toxics, 10(11), 711. https://doi.org/10.3390/toxics10110711
    • Mesnage, R., Benbrook, C., & Antoniou, M. N. (2019). Insight into the confusion over surfactant co-formulants in glyphosate-based herbicides. Food and Chemical Toxicology, 128, 137-145. https://doi.org/10.1016/j.fct.2019.03.053
    • Lehman, P. C., Cady, N., Ghimire, S., Shahi, S. K., Shrode, R. L., Lehmler, H.-J., & Mangalam, A. K. (2023). Low-dose glyphosate exposure alters gut microbiota composition and modulates gut homeostasis. Environmental Toxicology and Pharmacology, 100, 104149. https://doi.org/10.1016/j.etap.2023.104149

    Related reading